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ABSTRACT
Seasonal epidemics caused by influenza A viruses (IAV) result in an estimated
290,000- 650,000 deaths worldwide each year (17). While antivirals targeted to influenza
exist, resistance to these drugs is increasing and regular vaccination remains the most
effective way to prevent infection (26, 73, 99). However due to the persistence of antigenic
drift and shift, influenza vaccines must be updated each season and antigenic mismatches
can reduce efficacy (24, 118).
Immunity to influenza either from vaccination or infection is principally mediated by
antibodies generated to one of its major surface proteins, Hemagglutinin (HA). HA is a
homotrimer, each monomer HA0 is composed of a globular head and stem (100, 111).
Proteases present in the host cleave native HA0 into two subunits, HA1 and HA2. Residues
in HA1 form the receptor binding pocket within the head and facilitate interaction with the
host cell. The stem is encoded by both HA1 and HA2 and contains the fusion peptide
required for cytosolic release (10, 112). Most antibodies isolated from patients following
infection or vaccination are targeted to the receptor binding domain of the HA head. These
antibodies are efficient neutralizers but highly strain specific, recognizing only antigenically
similar strains of the same IAV group and consequently lose relevance rapidly as viruses
undergo drift (68, 141). However, patients immunized with heterosubtypic HA can also
develop antibodies that target the HA stem domain. These antibodies are often effective
against multiple HA subtypes, reflecting strong structural constraints imposed on the HA
stem epitope, and are referred to as “broadly neutralizing”. It is because of this strong
conservation that there has been an interest in characterizing HA stem antibodies in the
development of a universal flu vaccine (22, 115, 123). Since their discovery in 1991, dozens
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of broadly neutralizing stem antibodies have been isolated in humans and even more have
been derived using targeted technologies, including hybridoma cell generation (69).
We used two immunization protocols that each featured successive injection of
influenza with antigenically distinct HA components, H1 then H3, followed by hybridoma
cell development to generate candidate monoclonal antibodies (mAbs) targeted to the IAV
surface glycoproteins. We screened antibody containing hybridoma supernatant for activity
against influenza proteins using ELISA, Neuraminidase Inhibition (NI), and Hemagglutinin
Inhibition (HAI) assays. Those antibodies which showed appreciable activity against the
immunizing viruses from hybridoma generation were purified for further study. Of 114
antibodies, mAb 1G3 (IgG1) was found by Western blotting to successfully bind the HA
protein of H1, H1pdm, and H3 influenza A viruses as well as influenza B viruses of both
major lineages (Yamagata and Victoria). Significantly, mAb 1G3 was able to successfully
neutralize both influenza A and B viruses in vitro as shown by plaque assay and indirect
immunofluorescence of infected cells. 1G3 was also shown to be effective against H1, H3,
and an influenza B virus in ovo, delaying onset of positive viral titer and preventing viral
expansion overall.
Although we believe mAb 1G3 to have a conformational epitope, linear epitope
mapping revealed that 1G3 likely binds in the stalk domain near to the fusion peptide and
across the C terminus of HA1 and N terminus of HA2. We found this locus to be strongly
conserved among heterosubtypic influenza strains, including influenza B. Importantly, only
one other antibody known as CR9114 has been identified that can neutralize both influenza
A and B viruses in vivo (32). CR9114’s epitope appears to have significant overlap with the
proposed epitope of our mAb 1G3, although they are not identical.

xi

Where CR9114

displayed no activity against B viruses in vitro, 1G3 is the only antibody to date that inhibits
both A and B viruses in cells. This previously unseen neutralization profile may suggest the
possible presence of an additional inhibition mechanism or mechanisms active in cell
culture. While CR9114 prevents the fusogenic conformational change of HA within the host
endosome and incites Antibody Dependent Cellular Cytotoxicity (ADCC) in vivo, we have
demonstrated through Western blotting and neuraminidase inhibition that our mAb 1G3
likely also prevents extracellular HA cleavage and interferes with virion budding (11, 29,
122).
Therefore, mAb 1G3 is a unique and previously uncharacterized antibody that is
broadly neutralizing against Group 1 and Group 2 influenza A as well as both lineages of
influenza B.

xii

INTRODUCTION
The Centers for Disease Control (CDC) estimates that seasonal influenza epidemics
in the United States have been responsible for between 10 and 35 million cases of illness,
between 200,000 and 750,000 hospitalizations, and 12,000 to 60,000 deaths annually since
2010 (Figure 1). The total economic burden of each epidemic is projected to be about 87.1
billion dollars annually (17, 41). The 2017-2018 flu season was characterized as “severe” in
the United States across all age groups. At its peak, 7.5% of all outpatient visits were as a
result of influenza or influenza like illness, the highest levels seen since the 2009 swine flu
pandemic. Morbidity was above the national baseline for 19 weeks, making the 2017 flu
season one of the longest in recent years. 183 pediatric deaths from influenza were reported
to the CDC, the highest number for a seasonal epidemic since pediatric influenza motility
became a reportable condition in 2004 (17). While flu can be underestimated by the general
population, it is clearly a substantial public health concern.
Commonly known as the flu, influenza is a respiratory illness caused by influenza
viruses. Symptoms are non-specific and generally have a rapid onset which may include:
fever, cough, muscle aches, headaches, and malaise (17). Influenza infection can also
present with vomiting and gastrointestinal distress in young children and more rarely in
adults and seniors. Commonly spread in droplets, influenza virus is easily communicable
through coughing, sneezing, talking, and to a lesser extent, following contact with
contaminated fomites. Most people are contagious in the first 72 - 96 hours of illness and
may be able to transmit the virus up to 24 hours before symptoms begin.
Immunocompromised people as well as children may continue to shed virus and spread
disease for well over a week after symptom resolution (53).

Healthy adults can generally recover from an influenza infection with help from over
the counter treatment. However, some populations are at risk for serious complications.
Immunocompromised persons including the elderly and transplant recipients are especially
susceptible to severe disease and even death (17). The most common causes of death related
to influenza infection are secondary bacterial pneumonia and primary viral pneumonia, both
of which induce lung damage and pathology via the generation of immune infiltrates, free
radicals, and excess mucus (53). Influenza can also be particularly dangerous for pregnant
women and fetuses. The risk of stillbirth among vaccinated mothers is 51% lower than their
unvaccinated counterparts. Although the exact mechanisms remain unknown, it is believed
that fever and placental inflammation associated with influenza infection is correlated with
an increased risk of miscarriage and various birth defects including low birth weight and
even personality disorders like schizophrenia (46). It is recommended that all women who
become pregnant during the regular flu season receive the influenza vaccine, regardless of
their current trimester or gestational status (131). Another possible complication seen in
some populations is hemorrhaging from mucus membranes as a result of immune mediated
destruction of infected epithelial cells (3).
A subset of influenza strains possess a mutation which allows for growth outside of
the respiratory tract - causing a very high mortality rate of upwards of 80% (3). Known as
Highly Pathogenic Avian Influenza (HPAI), these viruses can be transmitted to multiple
critical organs, including the brain via the olfactory mucosa and then olfactory nerves where
the virus activates local glial cells (99). The resulting cytokine storm as well as TNFinduced mitochondrial mediated apoptosis causes extensive cellular damage and ultimately a
disruption of the blood brain barrier followed by rapid death (75). Fortunately, these viruses
2

are not easily communicable between people and are therefore not incorporated into the
seasonal vaccine.
In addition to seasonal epidemics, some influenza viruses can cause pandemics when
introduced to a novel human population. The H1N1 “Spanish Flu” of 1918 is estimated to
have killed between 50 and 100 million people worldwide – about 5% of the global
population at the time (89, 117). Other pandemic influenza events include “Asian” flu in
1957, the “Hong Kong” flu in 1968, and most recently the “Swine” flu pandemic of 2009.
The CDC estimates that there were almost 60 million cases of the “swine” flu in the United
States in 2009 alone (120).
Influenza Virus Structure
Influenza viruses are a group of respiratory pathogens belonging to the family
Orthomyxoviridae that are further divided into four genera: Influenzavirus A, B, C and the
most recently described D (33). Influenza viruses are characterized as having a single
stranded, negative sense RNA genome which is uniquely segmented. Influenza A and B
each contain eight viral segments while influenza C and D only contain seven. These
segments in turn encode viral proteins; with types A and B each producing at least 11 in vivo
as a result of alternative splicing and open reading frames (ORFs) (96, 100). Each RNA
segment is coated with nucleoprotein (NP) to form what is known as the viral
Ribonucleotide Nucleoprotein (vRNP) complex. vRNP complexes are assembled and
housed in many repeated matrix (M1) proteins. This viral core surrounded by a host derived
lipid bilayer acquired during budding from an infected cell (100). The virion surface features
two glycoproteins and one integral membrane protein, M2. All known naturally occurring
immunity is in response to the primary surface antigens, Hemagglutinin (HA) and
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Neuraminidase (NA) (132). Also present within an infectious virion are polymerase basic
proteins 1 and 2 (PB1 and PB2), which taken together with polymerase acidic protein (PA)
form the viral RNA dependent RNA polymerase (20). Additionally synthesized are
nonstructural protein 1 (NS1) which is critical for viral immune evasion, as well as nuclear
export protein/nonstructural protein 2 (NS2 or NEP). Virions are known to display a variety
of shapes, with the most well-known and abundant in vivo being roughly spherical (Figure
2) (42).
Influenza Virus Life Cycle
The influenza virus life cycle can be divided into the following stages: binding and
entry into the host cell, transport of genetic information into the nucleus, transcription of
viral proteins, export and translation, and finally assembly and budding at the host
membrane (Figure 3) (53).
Entry is facilitated by the binding of HA to sialic acid receptors on the host cell.
Different HA subtypes have varying affinity for each of the two major types of sialic acid
linkages found in nature. Neu5Ac α(2,3)-Gal is generally found within the gastrointestinal
tract of aquatic birds and deep in the human respiratory tract. Neu5Ac α(2,6)-Gal is found
throughout the length of the human respiratory system but is primarily concentrated in the
upper limits (84). Both types of sialic acid linkages are readily available in swine species
(94). Avian IAV strains generally have higher affinity for 2,3 linkages and circulating
human viruses for 2,6 linkages (43, 105). Following HA binding of either sialic acid
isoform, the virion enters the host cell in an endosome via receptor mediated endocytosis
(109). The low pH in the endosome provides the necessary acidic environment for both a
conformational change in HA and the activation of the M2 ion channel. HA subunits HA1
4

and HA2 disassociate at an acidic pH. This exposes the fusion peptide on HA2 that mediates
the fusion of the viral and host endosomal membranes, allowing viral contents to empty into
the cytoplasm (133). Opening of M2 ion channels causes further acidification within the
viral core, necessary for the release of vRNP complexes from the M1 matrix (42).
Because the influenza virus genome is composed of negative sense RNA, it must
first be converted to the positive sense before transcription can proceed. The virus carries
with it a viral RNA dependent RNA polymerase (vRNP) which initiates replication (6).
This polymerase is composed of 4 proteins: NP (Nucleoprotein), PA (Polymerase Acidic),
PB1 (Polymerase Basic 1), and PB2 (Polymerase Basic 2). None of these proteins have been
found to have proofreading ability, therefore the influenza polymerase is considered error
prone (139). Unlike other RNA viruses, influenza virus replicates within the host nucleus.
All protein components of the vRNP contain Nuclear Localization Signals (NLSs). These
viral proteins can use their NLSs as well as co-opt host nuclear import machinery to gain
passage along microtubules and eventually through nuclear pores (14). It is unknown
whether NLSs must be present on each individual protein or if some components of the
vRNP contribute to nuclear import more than others (11).
The PA component of the polymerase has endonuclease activity and participates in a
process called “cap snatching”, whereby the 5’ prime methylated caps of mature cellular
mRNAs are cleaved and used by the cellular RNA polymerase to prime viral transcription
(20). Cap snatching may also serve to protect viral mRNAs from being recognized by innate
host immunity, especially Toll Like Receptors (TLRs) and the RIG-1 system (133, 142).
Several segments of the IAV genome encode for multiple proteins products due to
alternative splicing and ORFs. Segment 8 encodes both M1 (Matrix 1) and M2 (Matrix 2)
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proteins while segment 7 is known to encode NS1 (Non-structural protein 1) and NEP
(Nuclear Export Protein) (6). As M2 and NEP are the secondary splice products, they are
generally found in much lower abundance than their counterparts M1 and NS1, respectively
(134). An important function of NS1 is to bind to components of the host spliceosome,
especially U6 small nuclear RNAs, and relocate them to the nucleus in order to sequester
splicing capabilities to local viral mRNAs (79). In addition to the 11 canonical IAV proteins,
other products have been recently described. In 2001 PB-F2 was identified as the result of
an ORF in the PB1 gene segment and appears to be implicated in in vivo infections,
especially in modulating host immunity and the apoptotic response (79, 100). PB1-N40, also
known as N40, is a third protein product from the PB1 gene. Recombinant viruses that lack
N40 display slower growth kinetics in vitro, but the exact mechanism and function or
functions of N40 are unknown (20, 79). The most recently discovered influenza protein has
been named PA-X, as it is a protein product from the PA gene segment. Infection studies of
viruses lacking PA-X have shown that it functions heavily in mediating the viral shut off of
host protein synthesis through cellular mRNA decay and is therefore a major virulence
determinant. Experiments are ongoing (50, 70)
Export of negatively sensed viral mRNAs from the nucleus through pores occurs
through the interaction of viral NP with host CRM1 dependent pathways. There also appears
to be a role for the M1 protein in the process, as viruses without M1 are deficient in protein
synthesis, although the mechanism remains to be elucidated (14, 18). Live imaging studies
have shown that NP proteins localize to the apical side of infected nuclei, implying an as of
yet unidentified mechanism of polarized exit from the host nucleus (68).
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Once translated by the host ribosomes, all viral components must assemble in the
cytosol and bud from the host cell’s plasma membrane. Influenza viruses use the host cell
membrane for the formation of the envelope and also as an aggregation point for proteins
needed for the progeny virions (98, 101). Two models have been proposed regarding
packaging of viral genomic segments into progeny virions. One model predicts that
segments are randomly packaged, and complete virions are the result of random probability.
Evidence cited by proponents of this model includes the well documented existence of
incomplete virions in cellular and in vivo infections (6). Noninfectious particles lacking a
complete complement of viral genes can and do form, but only virions with HA, NA, and
M2 can successfully bud from the host membrane (69). The other model is known as the
specific packaging model and hypothesizes there is an intrinsic system to encourage the
correct assembly of all necessary eight genomic segments and incomplete virions are as a
result of a failure of this system. This model is comparatively newer, but is thus far
supported by the discovery of packaging signals on the 5’ and 3’ ends of some viral
segments that appears to interact directly with lipid rafts (126).
Of critical importance during budding is the cleavage of sialic acid residues on the
infected host cell mediated by the Neuraminidase (NA) enzyme. Without productive NA,
progeny virions crowd at the cellular surface as a result of interaction between its HA and
intact sialic acid on the host surface. Trapped virions cannot move between cells and
therefore cannot propagate further infection (87).
Hemagglutinin (HA) and Neuraminidase (NA)
Because of their roles in the viral lifecycle and in mediating immunity, HA and NA are
the two most well studied influenza proteins and are used to classify different subtypes
7

influenza A viruses. To date, there are 18 subtypes of HA and 11 of NA, although not all of
these are able to readily infect humans (104).
Functional HA is a homotrimer with each monomer (HA0) composed of a globular head
and stalk anchored into the membrane at its C terminus (Figure 4). Synthesized as a single
polypeptide chain, HA0 undergoes significant post translational modification, including
glycosylation, palmitoylation, and eventually cleavage into its active subunits (42, 115,
132). HA is phylogenetically divided into 2 groups based on structural aspects of the stalk,
with H1 stalk structure defining group 1 and H3 defining group 2. The globular head is the
most variable domain of HA while the stem and membrane proximal domains feature a
conservation of sequence among IAVs ranging from 75-99% between HA groups 1 and 2.
HA from influenza B viruses has <75% sequence identity with any HA from IAV, although
the structure is highly conserved (42, 49).
Trypsin-like proteases present in the host cleave native HA0 into its subunits HA1
and HA2 at a single invariant arginine residue present on all HA subtypes except HA14
(109, 112). The N terminus of the newly formed HA2 relocates to the trimer interior,
however the subunits stay associated via disulphide bonds at amino acids 52 and 277 despite
cleavage (15, 107). During entry, HA1 binds to sialic acid on the surface of the host cell and
triggers endocytosis (22). The low pH of the resulting endosome causes a conformational
change in HA0 that exposes the fusion peptide present chiefly on HA2 (Figure 5). HA2
mediates a close association and eventual fusion between the viral membrane and that of the
late host endosome, allowing for the genetic content of the virion to enter the cytoplasm and
then the nucleus where replication can proceed (42, 117). Without cleavage of HA0 by
cellular proteases prior to endocytosis, the fusion peptide remains unavailable and the fusion
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of the viral and endocytic membranes cannot occur. In humans, this limits most influenza
viruses to the respiratory tract where the necessary trypsin-like proteases are produced;
including TMPRSS-2, Human Airway Trypsin 1, and possibly others which are still being
identified (11, 32).
The HA proteins of HPAI H5 and H7 viruses have additional basic residues at their
cleavage sites upstream of the invariant arginine (123). This allows for a larger number of
enzymes present in the avian and human host to cleave and activate the HA, including
ubiquitous proteases present in the liver, kidneys, and brain. This may explain why H5 and
H7 viruses have been demonstrated to grow in cell culture without supplemental trypsin as
well as outside of the human airway epithelium in vivo, causing severe and disseminated
disease (99). HPAI viruses have a mortality rate of roughly 60-80% in humans and between
90-100% in birds (3).
HA has two well described functions in the influenza viral life cycle. The head
serves to bind sialic acid on host cell membranes and facilitates viral entry. The stem and
fusion peptide associate the viral and host endosomal membranes to allow for uncoating.
Both roles are necessary; if HA1, HA2, or the HA0 monomer are compromised, infection
cannot proceed and either the virus will not enter the cell or the virus will be restricted to the
endosomal compartment (105, 117). Notably, there is also some data supporting an
additional HA function during packaging of progeny viruses, namely that the highly
conserved HA0 cytoplasmic tail directly impacts the ability of vRNPs to interact with lipid
rafts during virion assembly (132). The degree to which HA contributes to packaging is
unknown.
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Historically, influenza research has focused on HA because of its antigenic and
immunologic dominance in both natural and experimental infections. Recently however, NA
has gained attention both as a protein and as an antigen because of the advent of NA targeted
influenza inhibitors. NA is an exosialidase that cleaves α-ketosidic linkages between a sugar
and an adjacent N-acetyl-neuramic (sialic) acid. There are four main steps that comprise the
catalytic pathway of NA, beginning with binding followed by the donation of protons from
the solvent and the formation of a cation transition state intermediate. The final steps are the
formation and release of N-acetyl-neuramic acid (47). There are 11 NA subtypes among
influenza A viruses, those which can infect humans are divided into two groups based on
sequence phylogeny. The first group consists of N1, N4, N5, and N8 while the second group
includes N2, N3, N6, and N9 (2, 129).
Functional NA on a virion surface is a homotetramer of “boat propeller” or
“mushroom” shape. Each monomer is composed of 470 amino acid residues and has 4
domains: the cytoplasmic tail which anchors the protein at its C terminus, the
transmembrane domain, the enzymatically active head, and a thin stem (2) (Figure 6).
While NA from influenza A and B viruses only have roughly a 30% sequence homology,
their 3D structures are identical (103, 135).
The head is the most well studied NA domain. as it contains both the active site and
the calcium binding site which is indispensable as it stabilizes the conformation of the entire
tetramer. Residues which comprise the active site (Arg 118, Asp 151, Arg 152, Arg 224, Glu
276, Arg 292, Arg 371, Tyr 406) are highly conserved and found in all subtypes of influenza
A and B (104). The NA head also features major glycosylation sites which have been shown
to impact virus stability, enzymatic activity, as well as tissue targeting. Interestingly, a lack
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of glycosylation at Asn 146 has been demonstrated to be one of the major determinants of
the unique tropism of A/WSN/1933 (H1N1), a well-documented uniquely neuropathic
influenza (99). The characteristic fourfold symmetry of the NA tetramer is maintained by an
inward facing carbohydrate side chain on each monomer as well as bound metal ions. It has
been suggested that calcium binding may have physiological import in addition to structural
relevance in the context of a natural infection as a component of positive modulation of viral
activity within a host cell (47).
Data supports two main functions for NA during the influenza virus life cycle. The
most well studied role is in the final stages of budding as NA cleaves sialic acid found on
the virion to prevent aggregation of progeny at the host cell membrane (2). This was first
described by George Hirst in 1942 when he found that red blood cells were not susceptible
to re-hemagglutination by influenza virus following pretreatment with the same virus (54).
This was later solidified by a series of papers published by Peter Palese’s group in the
1970’s showing that virions with defective NA collect at the surface of infected cells (87).
A second less well explored role for NA is to allow penetration to the respiratory
epithelium by cleaving sialic acid from local mucins thus minimizing binding to irrelevant
receptors (47). Additional functions have also been suggested but remain poorly understood.
Some data suggests that NA may play a role in the synergistic relationship between
influenza virus and Streptococcus pneumoniae, as NA can serve to increase bacterial
adherence in the respiratory epithelium and may underlie the high incidence of secondary
bacterial pneumonia refractory to influenza infection in some patient populations (90).
Purified NA has also been shown to elicit a pro inflammatory cytokine response from
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alveolar macrophages, especially TGF-β, that may contribute to lung damage and overall
pathogenesis of influenza (53).
One of the most interesting things about influenza viruses is the presence of two
surface proteins which both recognize terminal neuraminic acid residues, but have
contradictory functions. Studies done in viruses that lack NA or HA activity or done with
artificial viruses obtained by reverse genetics show that these proteins act in concert, and
their ratios to one another are tightly regulated at the virion surface (129). Moreover,
phylogenetic analyses have demonstrated that these two proteins not only function together
but have evolved and continue to evolve in an interdependent manner (105). HA and NA
must function in a delicate balance to prevent the HA studding the surface of newly made
progeny from attaching to the surface of their parental host cell instead of moving away to
infect neighboring host cells. It is NA that affords freedom from the cell and the propagation
of infection by HA (43, 68).
Genetic Drift and Shift
All influenza viruses undergo continued change in response to host immunity, a
process of mutation known as antigenic drift (49). These minor changes that occur over time
because of point mutations in HA or NA are driven by positive selection of random
mutations enabling virus to subvert host antibodies; likely as a direct result of the error
prone viral RNA polymerase. Seasonal epidemics are generally due to drift away from the
previous season’s circulating virus (118). This process has also been documented in NA as a
result of anti-influenza antivirals that specifically target NA (133, 142).
While both influenza A and B viruses can undergo antigenic drift, only influenza A
viruses can participate in antigenic shift (49, 118). Where drift is described as a slow change
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over time, shift is when a novel HA or NA is introduced into a human population from an
animal reservoir and can result in a new, pandemic virus (Figure 7). Antigenic shift is
usually caused by of a reassortment of genes, where the shuffling of independent gene
segments from at least two different virus occurs as a result of infection in the same host cell
(80). The three most recent human influenza pandemics were each caused by reassortment
within influenza A viruses. The “Asian Influenza” in 1957 and the “Hong Kong Influenza”
in 1968 were caused by reassortment events between human and avian viruses (9, 126). The
2009 “Swine Flu” pandemic strain was a triple reassortant of human, avian, and swine
influenza viruses (120). Swine are an important animal host for influenza and are often
referred to as a “perfect mixing vessel” because they express both types of glycosidic
linkages found in aquatic birds and the human upper respiratory tract. This availability of
both 2,3 and 2,6 glycosidic linkages encourages recombination between avian and human
viruses (94, 120). The ability to undergo both drift and shift is an incredible evolutionary
advantage for influenza virus which underlies the necessity behind a consistently updating
seasonal vaccine as well as highlights the challenges of developing universally applicable
control strategies.
Vaccination Strategy and Antivirals
The first drugs developed to control influenza infections were M2 ion channel
inhibitors (5). The M2 ion channel is a proton pump active following endocytosis of the
virion into the host cell. Without a properly functioning M2 channel, the genome is not be
able to uncoat from the M1 matrix and the replication cycle is arrested (5, 114). Amantadine
was developed in the late 1960’s as prophylaxis in response to the 1968 Hong Kong Flu
pandemic followed quickly by Rimantadine. Mechanistically, both appear to bind the inward
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facing lipid pocket and block proton translocation although there is some degree of debate
about a second drug interaction site (91). The official CDC guidelines now suggest a total
moratorium on the use of M2 ion channel inhibitors as widespread resistance developed
while resistant viruses have maintained identical infectious and pathogenic properties. A
survey from 2009 showed 100% of wild type H3N2 viruses as well as 100% of non
pandemic H1N1 viruses were resistant (114, 124).
Drugs that targeted the viral NA were also first discovered in the 1960s. The first
anti-NA drug was a transition state analogue known as DANA. While effective in vitro,
DANA failed to perform well in vivo as it could not readily cross cellular membranes and
was very quickly metabolized (40). Following the successful crystallization of N2, it was
theorized that the addition of a 4-guanidino group would improve binding to the catalytic
site and led to the creation of Zanamivir (RelenzaTM). The same crystal structure was used
by competing scientists to design Oseltamivir (TamifluTM) with the promise of easier of
synthesis and greater bioavailability, as well as the option of oral administration (129). Wild
type influenza viruses with resistance to both types of available NA inhibitors have been
isolated, but unlike what has been observed with M2 inhibitors, resistance is often associated
with a decrease in viral fitness (52, 138). However in 2008, an H1N1 virus with a
substitution in NA at position 275 and a compensating mutation in HA was found to be
resistant to inhibitors while maintaining infectivity. This clade of virus was quickly replaced
in the population by the 2009 “Swine Flu” H1N1 virus (H1N1pdm09), but this emergence
remains one of many troubling facts that undermines confidence in our current reliance on
NA inhibitors in clinical settings (120).
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In addition to the ever-looming threat of resistance mutations, NA inhibitors have
their own set of clinical limitations. Because NA functions at the end of the viral life cycle,
patients must begin their course of NA inhibitors very early in symptomatic onset. Its
recommended that patients begin Oseltamivir or Zanamivir within 48 hours of falling ill,
which presents a challenge as many patients do not seek medical intervention so early in
clinical disease course (47, 91). Additionally, several large-scale retrospective studies have
called into question whether NA inhibitors work at all in most clinical settings, with the
general consensus being that drug intervention results in only a one day reduction in illness.
In fact, some medical professionals report having serious doubts about the efficacy of NA
inhibitors and often only prescribe them to patients who make a request (39, 59). This
coupled with widely reported side effects that include gastrointestinal distress make NA
inhibitors far from an ideal treatment for influenza infection.
The newest drug developed for influenza infection is S-033188 or Baloxavir
marboxil, marketed as XofluxaTM. Developed by Shionogi Co in Japan and recently
acquired by Roche, Baloxavir is a small molecular inhibitor of the cap dependent
endonuclease (51). This endonuclease is found on the N terminal domain of the PA subunit
of the influenza RNA dependent RNA polymerase and mediates a process known as “cap
snatching” (27). Translation of mRNA in human cells requires that transcripts are capped at
the 5’ end. The viral endonuclease cleaves caps from host mRNA allowing them to serve as
primers for viral mRNA. Mutations in the endonuclease domain of PA are rare and often
result in a decrease in viral fitness, making this location an ideal target for inhibitor therapy
(27, 139). Studies have shown that a single dose of Baloxavir was superior to both placebo
and Oseltamivir in relieving influenza symptoms and decreasing viral titers. Unlike
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Oseltamivir, Baloxavir showed efficacy up to five days post symptomatic onset and has a
more favorable safety profile as Oseltamivir often presents with gastrointestinal distress (51,
92). Already approved in Japan, Baloxavir was given a “Priority Review” status by the
Federal Drug Agency and approved in October of 2018. It became available to American
patients and prescribers before the end of 2018 and costs roughly $150 USD without health
insurance, the same as a course of TamifluTM despite being a single dose pill (51).
While drugs for mild infection are very limited, there is no drug currently licensed
for those who are hospitalized with influenza, although NA inhibitors have been used off
label for this purpose to mixed success (129). Therefore, regular seasonal vaccination
remains the best option to both prevent illness and combat potential pandemics (Table 1).
While the intranasal live attenuated vaccine (LAIV) has been recently re-added to the CDC
recommendations, the current standard of care for all people between 6 months and 65 years
of age is the quadrivalent inactivated vaccine (QIV). Other formulations are available,
including a high dose vaccine designed for those over 65 years old who may be generally
weak responders to vaccination (17).
The QIV is composed of two inactivated influenza A strains and two inactivated
influenza B strains. Each of the four strain components are determined to be biologically
relevant for the coming flu season by the CDC pursuant to global recommendations from the
World Health Organization (131). While the flu season may start in the fall, strain
recommendations are generally made for the Northern Hemisphere vaccine in February.
This allows manufacturers time to prepare reagents and viral components, which must be
specific to the viruses in that year’s vaccine, for some 160 million doses. Pharmaceutical
companies typically start manufacturing vaccine ahead of official recommendation
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announcements in order to have the vaccine ready for distribution as soon as possible;
although this puts them at significant financial risk if recommendations change. Vaccine
strain selection is a multi-factorial process that requires input from scientists and influenza
experts from around the world in addition to epidemiological algorithms that predict the
upcoming season based on data from the opposite hemisphere as well as epidemics from the
previous year (17, 131). Despite the incredible amount of effort and data analysis that goes
into vaccine strain selection, there is the opportunity for error when chasing an ever-moving
target. Vaccine mismatches can happen that would leave even healthy, vaccinated,
individuals vulnerable to infection (24). It also possible that any one or a combination of the
circulating viruses chosen will make significant antigenically relevant changes between
strain selection in February and vaccine delivery to points of care in the early fall (120).
Despite many obstacles, vaccine efficacy is generally between 30 and 70% (16, 48,
118). The quadrivalent inactivated vaccine for the 2017-2018 season had an overall efficacy
of 40% against all four strains, meaning a vaccinated individual was 40% less likely to seek
medical care for flu. H3N2 viruses generally dominated the season, and strain specific
efficacy of the vaccine against the H3N2 virus was 25%. There were 184 pediatric deaths;
between 80 and 90% of deceased children were unvaccinated (17). While the 2018-2019
season is ongoing, interim estimates from the CDC show a H1N1pdm dominant season with
a slightly higher vaccine efficacy of nearly 50%. As of February 2019 seasonal influenza
may have caused as many of 17.8 million cases of illness and 19,000 deaths in the United
States (17). Even when vaccine efficacy is low or in seasons with a considerable mismatch,
studies have shown that vaccination still reduces the need for hospitalization (81, 86, 119).
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In the 1960’s, Dr. Edward Kilbourne invented a technique of exploiting viral
antigenic shift in a controlled laboratory setting to introduce desired characteristics for
vaccine production into wild type viruses (62). This process, known as classical
reassortment, was first used in vaccine production in 1971 and is still used by our laboratory
and others in the United States and around the world.

Using classical reassortment,

candidate vaccine viruses are selected to express the circulating HA and NA proteins of
those viruses recommended by the CDC but contain the internal genes of a high growing
donor virus, A/Puerto Rico/8/1934 (PR8). The resulting reassortant viruses are designated
high yield reassortants (HYRs), as the inclusion of PR8 internal genes often results in an
upregulation of viral growth when injected into embryonated chicken eggs (63). An increase
in protein/antigen output is highly desirable to manufacturers as it makes producing the
vaccine less costly and more efficient.
Because of influenza virus’ segmented genome, co-infection of a single egg with two
viruses results in a possible 256 distinct viral progeny. Selection of candidate reassortment
viruses from the viral population present within an egg is accomplished by applying
polyclonal antibodies to PR8 HA and NA. This inhibits the growth of those viruses
expressing PR8 donor glycoproteins on the surface and encourages expansion of the wild
type HA and NA bearing viruses. Candidate HYR seed viruses are then cloned by limiting
dilution and fully characterized in sequence and antigenicity in house and by government
regulatory agencies before being sent to manufacturers for large scale production in eggs.
The process of generating seed viruses is a rate limiting step in vaccine production and can
vary in time depending on properties of the wild type target, taking on average about four
weeks (41, 96).
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HA Antibodies and Hybridoma Technology
One of the newest approaches to combating influenza is the use of antibodies (Abs).
It has long been known that there is therapeutic benefit to treating serious influenza
infections with convalescent plasma, especially in cases of HPAI infection (22). The vast
majority of antibodies isolated from people either after a naturally occurring infection or
vaccination are targeted to the immunodominant HA. Of these, the highest percentage are
targeted to the variable loops surrounding the receptor binding site within the HA head
domain.

These antibodies function to neutralize virus by preventing viral entry via

inhibition of interactions with sialic acid (11). These antibodies are effective but highly
strain specific, recognizing only antigenically similar strains of the same group and therefore
lose relevance rapidly over time as viruses undergo shift and drift (40, 115).
Rarely, a patient may develop an antibody that instead of targeting the HA head
targets the membrane proximal or HA stem domain. These antibodies are often broadly
neutralizing and able to inhibit many viruses even across IAV group. The unique cross
reactivity of stem antibodies reflects the strong structural constraints imposed on the HA
stem epitope as a result of the necessity of its function (121). The stem itself is composed of
the N and C terminal domains of HA1 (1-52, and 277-345 H3 numbering) as well as the
entirety of the N terminal region of HA2 (109). The accepted demarcation between the HA
stalk and head is a disulfide bond between two cysteine residues at amino acids 55 and 277
(69). Because of its conservation, there has been a growing interest in characterizing HA
stem antibodies as the basis of a universal vaccine – a vaccine that may one day be able to
prevent infection by all influenza A and B subtypes. Since their discovery in 1991, well over
a dozen stem antibodies have been isolated in humans in response to heterosubtypic HA
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vaccination and more have been derived using targeted technology, including hybridomas
and single B cell isolation (65, 80).
Most patient derived HA stem antibodies thus far characterized share common
features that may elucidate possible in vitro and in vivo protection mechanisms. While their
exact epitopes differ, generally it lies around or across the HA1/HA2 cleavage site, meaning
mAb binding depends on residues found on both HA1 and HA2 subunits (24, 80). Unlike
HA head antibodies which inhibit receptor binding, these antibodies target influenza in a
multitude of ways both intracellularly and extracellularly and can work at many steps in the
viral life cycle. Stem antibodies have been shown to be able to be internalized as a complex
with viral particles during receptor mediated endocytosis, and therefore act between entry
and exit in the viral life cycle within the host cell (11). Here, binding to the stalk of an
incoming HA may inhibit pH induced conformational changes that would normally expose
the HA fusion domain, preventing viral and endosomal membrane fusion (115, 133).
Another proposed mechanism involves averting the extracellular cleavage of HA0 into HA1
and HA2 by local cellular trypsin-like proteases via site occlusion. This is supported by data
suggesting that some stem targeting antibodies with footprints overlapping the protease
recognition site are not capable of neutralizing HPAI viruses. These viruses have a
multibasic site mutation and are cleaved intracellularly instead of extracellularly unlike most
other influenza viruses and are therefore precluded from antibody recognition if internalized
unbound (42). While HA stem antibodies do not directly bind NA, they have also been
shown to inhibit NA activity in vitro through steric hindrance because of the close physical
proximity of HA and NA on the virion membrane (68). In vivo protection is likely
modulated by these mechanisms in addition to others, including ADCC as well as activity
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through FCγ receptors on immune cells (28). It is likely a combination of these means and
others yet undiscovered coupled with the unique conservation of the HA stem that make
stem antibodies so effective at limiting influenza replication in vitro and in vivo and a very
attractive target for vaccine design and therapeutics.
HA stem directed antibodies have been found in human plasma in response to
vaccination with more than one HA subtype, but there has also been a concentrated effort to
design antibodies targeted to the HA stem. While polyclonal antibodies represent the entire
B cell repertoire to an antigen, a monoclonal antibody (mAb) is the result of a single B cell
producing one antibody to a specific epitope of that antigen. MAbs are therefore more
specific and consistent in a translational context and can be easily modified to be appropriate
for administration to humans (106). MAbs can be created using a variety of techniques,
including hybridoma technology (Figure 8). Using this method, splenic B cells from a
mouse immunized against the desired target antigen are fused with myeloma cells to
produce hybridoma cells. Hybridoma cells produce antibody like the parental B cell as well
as have the ability to divide indefinitely like the parental myeloma cell (56). Successfully
fused cells are selected using specialty HAT media which contains hypoxanthine,
aminopterin, and thymidine. This blocks the de novo nucleic acid synthesis pathway and
forces cells to rely on salvage synthesis for DNA and RNA. Unfused splenic cells die
quickly due to their short life span and limited doubling capacity. Unfused myeloma cells
lack hypoxanthine guanine phosphoribosyl transferase (HGPRT) and are unable to
participate in salvage synthesis and therefore also die. The only cells capable of survival in
these conditions are successfully fused hybridoma cells. These cells are selected, screened
by the method of investigator choice, and finally cloned by limiting dilution so identical
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mAbs can be continuously and reliably be produced in cell culture (45).
Through the screening of hybridoma cell lines developed in response to
heterosubtypic influenza vaccination of mice, we believe we have generated a novel
monoclonal antibody 1G3 (IgG1) targeted to the stem of the influenza HA that may provide
insight into shared influenza epitopes and eventually new vaccination and treatment
modalities.
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Figure 1: CDC estimates for number of cases, hospitalizations, and deaths as a result of
seasonal influenza infection each year in the United States. Precise calculations are made
difficult as many patients will not seek care for mild illness. (17)
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Figure 2: Influenza viral structure (on right), shown with spherical morphology. Eight
segmented genome segments are shown on the interior of the virion according to descending
size. Major surface glycoprotein Neuraminidase (NA) is in red, Hemagglutinin (HA) is
shown in blue, while the M2 ion channel embedded within the viral envelope is depicted in
green. An individual viral ribonucleoprotein (vRNP) complex is visible to the left of the
virion. The viral RNA dependent RNA polymerase is composed of PA, PB1, and PB2. (24)
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Figure 3: Influenza A virus life cycle shown with steps labeled from left to right across the
infected host lung epithelial cell. This include binding, receptor mediated endocytosis of the
virus, fusion of the viral and host endosomal membrane and uncoating of the genome from
the viral core. This is followed by replication and transcription in the host cell nucleus,
translation and assembly in the cytoplasm, and release as the host cell surface. Image
created with BioRender©
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Figure 4: A) A complete influenza A HA monomer, known as HA0, with subunits HA1 in red
and HA2 in green. The globular head and stem domains are technically distinguished by a
disulphide bond noted at C52 and C277. B) A native HA homotrimer as it would sit in the
membrane of the virus or a host cell with the head facing externally. The basic subunits and
domains of HA protein include HA1 and HA2. The HA head is primarily encoded by HA1,
while the stalk is composed of the N and C terminal ends of HAI as well as the majority of
HA2. HA phylogenetic tree demonstrating the separation of HA into two groups based on
stalk sequence. The HA subtypes circled in red circulate as seasonal pandemics while those
in green are associated with Highly Pathogenic Avian Influenza (HPAI). (115)
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Figure 5: Ribbon diagram of engaged trimeric influenza A HA. Proteolytic activation by
trypsin-like proteases occurs extracellularly for seasonal viruses at the cleavage loop
(yellow) yielding distinct HA subunits HA1 (blue) and HA2 (red). HA1 and HA2 stay
associated via disulphide bonds throughout binding and endocytosis until low pH present in
the host endosome facilitates rearrangement to expose the fusion peptide. The fusion peptide
is then free to embed itself in the host endosomal membrane and facilitate the merging of the
host and viral membrane. (42)
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Figure 6: Left) The phylogenetic tree of all known neuraminidase (NA) subtypes within
influenza A and B viruses. Green denotes influenza A Group 1 with is typified by the N1
protein common in seasonal as well as some HPAI viruses. The yellow lines represent
influenza A Group 2, this includes N2 which is also common in seasonally circulating
viruses. Shown in blue are the NA proteins from influenza B viruses, which share about half
of their sequence with those from influenza A viruses. Right) Top down ribbon diagram of
influenza A N1 based on X-ray crystallography. Its characteristic “boat propeller“
formation is highly conserved between influenza A and B viruses despite considerable
sequence
variation.(99)
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Figure 7: Top) Antigenic drift in both influenza A and B viruses is caused by small
mutational changes introduced by the error prone viral polymerase. These changes may
select for viruses which drift away from neutralizing epitopes and prevent immune
recognition - resulting in regular seasonal epidemics. Bottom) Antigenic shift is the
introduction of novel proteins into a naïve population. Shift of influenza A viruses can result
in pandemic strains. Shift is illustrated here as a triple reassortment in a swine intermediate
host resulting in an HA protein not previously seen in humans - as was the case in the 2009
“Swine Flu”. Influenzas B and C are not known to participate in shift as they have no
substantial animal reservoir. (94)
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Table 1: Currently licensed flu vaccines in the United States for the 2017-2018 influenza
season. The general standard of care is the intradermal quadrivalent inactivated vaccine
which is recommended for all people between 6 months and 65 years of age, including
pregnant women and the immunocompromised. The recombinant vaccine, FluBlok™, was
approved in 2013 and does not use an egg-based manufacturing scheme. Previously, the live
attenuated vaccine marketed as FluMist™ was not recommended due to poor efficacy data
but is now available to some patients. Also offered are high dose formulations for patients
over 65 years of age. (17)
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Figure 8: Hybridoma cells are generated via the fusion of splenic B cells isolated from an
immunized mouse and myeloma cells to form stable antibody producing cell lines using
specialized fusion and selection media. Hybridomas can divide indefinitely and serve as a
renewable source of standardized and specific monoclonal antibodies. (56, 71, 88) Image
created with BioRender©
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SPECIFIC AIMS
Aim 1. Develop and purify anti-Flu Monoclonal Antibodies (mAbs)
1. Generate candidate mAbs via hybridoma technology following mouse immunization
1.1.

Immunization Protocol Alpha: Immunization with A/Puerto Rico/8/1934
(H1N1) and NYMC X-162 (H3N1, A/Wisconsin/67/2003 HA donor) HA and
NA protein preparations

1.2.

Immunization Protocol Beta: Co-immunization of A/Puerto Rico/8/1934
(H1N1) and NYMC X-162 (H3N1) HA and NA protein preparations with
anti-HA head mAb 2A6 (IgG1)

2. Identify potential candidate mAbs
2.1.

Neuraminidase Inhibition (NI) assay against A/Puerto Rico/8/1934 (H1N1)
and NYMC X-162 (H3N1) using both hybridoma supernatant and purified
antibody candidates

2.2.

Hemagglutinin Inhibition (HAI) assay against A/Puerto Rico/8/1934 (H1N1)
and NYMC X-162 (H3N1) using purified antibody candidates

3. Isotype and purify candidate mAbs

Aim 2. Characterize binding profile and epitope of candidate mAbs
1. Investigate binding profile of candidate mAbs
1.1.

Western blotting against infected allantoic fluid and purified viruses;
including immunizing viruses A/Puerto Rico/8/1934 (PR8, H1N1) and
NYMC X-162 (H3N1) in addition to heterosubtypic viruses (H1N1, H1N1
pandemic, H3N2 viruses, influenza B viruses)
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2. Map the epitope(s) of each candidate mAb using
2.1.

In silico sequence alignment of bound viruses from Aim 2.1.1

2.2.

Epitope mapping via overlapping peptide array

Aim 3. Evaluate candidate mAbs efficacy in vitro and in ovo
1. Demonstrate quantitative in vitro inhibition of viral activity by candidate mAbs via
Plaque Reduction and Neutralization Tests (PRNT)
1.1.

Testing plaque number and size reduction capability of antibody candidates
as hybridoma supernatants against immunizing viruses A/Puerto Rico/8/1934
(PR8, H1N1) and NYMC X-162 (H3N1) in addition to heterosubtypic
viruses (H1N1, H1N1 pandemic, H3N2 viruses, and influenza B viruses)

2. Demonstrate qualitative in vitro inhibition of viral activity by candidate mAbs via
fluorescent microscopy of infected cells
2.1.

Fixed fluorescent staining of A/Puerto Rico/8/1934 (PR8, H1N1) HA
following infection then treatment with candidate mAbs or isotype control

3. Compare viral growth curves in ovo of immunizing viruses A/Puerto Rico/8/1934
(PR8, H1N1) and NYMC X-162 (H3N1) in addition to an influenza B virus
following co-incubation of virus and candidate mAbs
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MATERIALS AND METHODS
Mouse Immunizations
Eight six month old female BALB/C mice (POCONO FARMS) were immunized for
hybridoma preparation. On Day 0 mice were bled were for a pre-immunization baseline and
then injected intraperitoneally with 25 μg purified A/Puerto Rico/8/1934 (H1N1)
hemagglutinin and neuraminidase antigen in Freund’s adjuvant. This was repeated on Day
14. On Day 28 mice were injected with 25 μg purified NYMC X-162 (H3N1,
A/Wisconsin/67/2014 HA parent) hemagglutinin and neuraminidase antigen in Freund’s
adjuvant. On Day 40, mice were bled and sera tested for response to A/Puerto Rico/9/1934
antigen by ELISA. On Day 45 mice were given a final 25 μg A/Puerto Rico/8/1934
hemagglutinin and neuraminidase antigen boost intravenously before being sacrificed on
Day 47 or 48.

Hybridoma Preparation
Following sacrifice, murine spleens are harvested and splenic cells are suspended in serum
free hybridoma media (THERMO FISHER) and counted. X63 murine myeloma cells
(ATCC) are added directly at a ratio of 1:2 and centrifuged together. 1.5 mL polyethylene
glycol (PEG) for every 3x10 mixed cells is very slowly added before centrifuging the
8

solution again at 1000 rpm for 5 minutes. Hypoxanthine-aminopterin-thymidine (HAT)
media (THERMO FISHER) is added and the fused cell suspension is divided into flasks
prepared with warmed HAT media. Flasks are gently swirled to ensure an even cellular
distribution and then cells and 2mL media are aliquoted into 24 well plates to be incubated
at 5% CO and 37 C. After 10-14 days wells with visible color change from acidic cellular
2
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replication by-products are tested for antibody production by ELISA. ELISA positive wells
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are sub-cloned into 96 well plates for primary screening and then transferred to flasks for
continuing culture.

Antibody Isotyping
Antibody isotyping is done via Murine Antibody Isotyping Kit (PIERCE). Candidate
hybridoma cell culture supernatant is diluted with the sample diluent to a final concentration
of 1:1000 and vortexed. 150 μl of the diluted sample is added to the testing cassette and
incubated at room temperature for 10 minutes. A successful typing is characterized by a red
band at the control mark and a dark band at one of the isotypes markered on the cassette.

IgG Antibody Purification
The cell culture supernatant of candidate hybridomas is centrifuged at 6000g for 5 minutes
to remove any cellular debris. The G protein column is equilibrated with 75 ml PBS and the
supernatant is diluted two fold with PBS to a final volume of 600 mL and directly applied to
the column followed by 100 mL PBS to wash the column. Bound monoclonal antibody is
eluted from the column with 75 mL 0.1 M glycine (pH 2.7) and approximately 2 mL per
fraction is collected in 5 mL tubes with 40 μl 1 M Tris-HCl (pH 9.0). Absorbance at 280 nm
is measured for each fraction, and all fractions with an absorbance more than 0.5 are pooled
into a clean 15 ml conical tube. The pH of the purified mAb is determined by pH paper and
adjusted to 7.0 by neutralizing buffer. Antibody solutions are then run by Western blot in
reducing and non reducing conditions and stained with Coomassie blue to assure purity.

Antibody Concentration Measurement
The concentration of purified monoclonal antibodies is determined by Bradford assay (BIORAD). Five linear-range dilutions of the bovine gamma immunoglobulin standard and
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purified antibody are prepared. 800 μl of each standard and sample solution is incubated
with 200 μl dye reagent concentrate at room temperature for 5 minutes. Absorbance is then
measured at 595 nm. The concentration of purified antibody is calculated from the standard
curve. All protein solutions are assayed in duplicate.
Virus Amplification
Viruses are amplified in 11 day old embryonated Specific Pathogen Free (SPF) chicken
eggs. A virus dilution of 10 is prepared in phosphate buffered saline (PBS) with 25 μg/ml
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gentamicin (SIGMA). 0.1 mL of the viral dilution is injected into each egg. After incubation
at 35 C for 48 hours, the eggs are placed at -20 C for 1 hour and then 4 C for at least 2
0

0

0

hours. Then allantoic fluid containing virus is harvested from the eggs. The titer is
determined by hemagglutination assay and plaque forming units per mL (PFU/mL) is
determined by plaque assay.

Neuraminidase Assay
50 μl of hybridoma cellular supernatant is first added to a glass 16 X 125 mm tube
(FISHER). 50 μl virus diluted to desired concentration in PBS supplemented with 2mM
calcium. PBS with calcium without virus is used as a negative control. Following 30 mins
incubation at room temperature, 100 μL of fetuin diluted in 0.4M phosphate buffer (pH 5.9)
is added to each tube. Tubes are vortexed and incubated in a 37 C water bath for 16-18
0

hours. 0.1 mL periodate is then added to each tube. Following a 20 minute incubation at
room temperature, 1 mL arsenite is added. Tubes are agitated by hand until the solution
turns from dark brown to clear or opaque. 2.5 mL of thiobarbituric acid is added and tubes
are vortexed. Tubes are then placed in a boiling water bath for 15 mins. The mixture is
allowed to reach room temperature before 4 mL acid butanol is added. Tubes are briefly
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vortexed and then centrifuged for 2 mins at 1000 RPM. The optical density read at 549
nanometers by spectrophotometer.

Hemagglutination Assay
50 μl phosphate buffered saline (PBS) is added to each well of a V bottomed 96-well
microtiter plate. 50 μl of purified virus or virus suspended in allantoic fluid is added into the
first well of each row. A 2-fold serial dilution (1:2, 1:4, 1:8, etc.) is made by carrying 50 μl
of solution from well to well across the plate. 50 μl PBS and virus left in each well are
incubated with 50 μl 0.5% chicken red blood cells at room temperature for 30 minutes after
30 seconds of agitation. The virus titer is read as the lowest dilution ratio of virus without
visible hemagglutination.

Western Blotting
0.1 μg viral protein or 10 μL of infected allantoic fluid is loaded into NuPAGE Novex 412% Bis-Tris precast gel and separated using the XCell SureLock Mini-Cell electrophoresis
system (INVITROGEN). The proteins are transferred onto polyvinylidene difluoride
(PVDF) membrane and probed with antibody containing hybridoma cellular supernatant
overnight at 4 C. Near infrared fluorescent anti-mouse IgG secondary antibody (LICOR)
0

diluted in blocking buffer (LICOR) is then incubated with the membrane for 1 hour at room
temperature. Blots are washed four times before scanning using an Odyssey membrane
scanner (LICOR).

Cell Culture
Madin-Darby canine kidney (MDCK) cells were purchased from American Type Culture
Collection (ATCC). Cells are grown in Eagle’s Minimum Essential Medium (EMEM,
37

GIBCO) supplemented with 10% fetal bovine serum (FBS, GIBCO), 10 units/mL penicillin
(SIGMA), and 10 μg/mL streptomycin (SIGMA) at 5% CO and 37 C. FBS is denatured at
0

2

56 C for 30 minutes prior to use. For subculture, cells are grown to 80% confluency before
0

detached from culture flask using trypsin-EDTA (SIGMA).

In vitro Plaque Reduction Neutralization Test
MDCK cells are seeded in 6-well plates (CORNING) at a density of 0.5-1x10 cells per well
5

in 4 ml of growth medium. When approximately 80-90% confluency is achieved after 48
hours, the growth medium is removed and wells are washed with 2 ml PBS supplemented
with 0.2% bovine serum albumin (BSA, SIGMA). Each well is then inoculated with 0.2 mL
virus diluted to desired PFU. After incubation at 5% CO and 37 C for 30 minutes the virus
2

0

inoculum is removed. Each well is then covered with an agar overlay composed of Minimal
Essential Medium (MEM, ATCC), 2 μg/mL trypsin (WORTHINGTON), and 0.01%
Diethylaminoethyl (DEAE) dextran supplemented with hybridoma cell culture supernatant
or purified monoclonal antibody. 72 hours post infection the overlay is removed and plaques
are visualized by staining with 0.1% crystal violet in 20% ethanol for 15 minutes at room
temperature.
Indirect Immunofluorescence
MDCK cells are seeded into 6 or 8 well chamber slides (NUNC). Cells are incubated at at
5% CO and 37 C and reach 80 to 90% confluency at 12-18 hours. Each well is then
2

0

inoculated with 0.2 mL A/Puerto Rico/8/1934 (H1N1) diluted to desired PFU in PBS
supplemented with 0.2% bovine serum albumin (SIGMA). Following 30 mins at 37 C, the
0

viral inoculum is removed and replaced with growth media or growth media supplemented
with purified monoclonal antibody. The chamber slides are incubated at 5% CO and 37 C
2
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0

for 48 hours. The cellular monolayer is fixed with 3.7% paraformaldehyde for 30 mins at 4
0

C and then rinsed with PBS. Cells are incubated with 5% bovine serum albumin (SIGMA)

in PBS for 1 hour at room temperature. Primary antibody is diluted in 1% bovine serum
albumin (SIGMA) and incubated with the cells overnight at 4 C. Next, the cells are washed
0

with PBS and incubated with the anti-mouse IgG Alexa Fluor 488 secondary antibody
(JACKSON LAB) for 1 hour at room temperature. Following a final wash, the cells are
incubated with 4’6,-diamidino-2-phenylindole (DAPI, THERMO FISHER) for 5 mins and
mounted with coverslip.

In ovo Inhibition Test
11 day embryonated Specific Pathogen Free chicken eggs (CHARLES RIVER) are first
“windowed” by removing a 1 cm square portion of the shell. Virus is diluted to 10 in PBS
-8

supplemented with 25 μg/mL gentamicin (SIGMA) and then incubated with purified
monoclonal antibodies for 30 mins at 37 C. 0.1 ml of the virus-antibody solution is injected
0

into each windowed egg and the window is sealed UV sterilized parafilm sealed to the intact
shell with melted paraffin wax. The parafilm is removed and 150 μl of allantoic fluid
collected every 12 hours before resealing the window. Eggs are incubated for a total of 72
hours at 37 C for influenza A viruses, or 96 hours at 33 C for influenza B viruses. The viral
0

0

titer of allantoic fluid is determined by hemagglutination assay.
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EXPERIMENTAL RESULTS
Aim 1. Develop and purify anti-Flu Monoclonal Antibodies (mAbs)
During the completion of his dissertation in our laboratory, Dr. Yu He began
experiments with the intention of generating monoclonal antibodies (mAbs) targeting the
hemagglutinin (HA) and neuraminidase (NA) proteins of A/Puerto Rico/8/1943 (PR8) for
use during the generation of candidate vaccine viruses. MAb secreting hybridomas were
produced from the harvested spleens of animals enrolled in an immunization protocol
referred to as Alpha (Figure 9). Briefly, eight female BALB/C mice were immunized
intraperitoneally with PR8 H1N1 HA and NA protein preparation followed by
heterosubtypic NYMC X-162 H3N1 preparation. NYMC X-162 is a high yield reassortant
(HYR) virus which has the HA gene from A/Wisconsin/67/2005 (H3N2) but the NA and
remaining internal genes of PR8. Antigen was prepared for injection by amplification in
specific pathogen free embryonated chicken eggs. HA and NA proteins were co-purified
using high speed centrifugation and sucrose gradient. Following inoculation, mouse sera was
then collected and screened via ELISA against PR8 HA and NA on Day 40 post injection.
Animals with positive ELISA results were given a final PR8 HA+NA protein boost
intravenously on Day 45 and then sacrificed. Isolated spleen cells were fused with myeloma
cells to form stable antibody producing hybridoma cells which were then cloned and
screened (Figure 8).
From Immunization Protocol Alpha, we were able to establish 114 hybridoma cell
lines targeted to influenza surface glycoproteins HA or NA. The antibody containing
(conditioned) supernatant of these cells was then screened for reactivity against HA or NA
by Western blot using recombinant PR8 HI HA (rHA). Initially, we were interested in an
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antibody to the PR8 NA as Dr Yu He had previously characterized several HA antibodies.
Of 114 hybridoma supernatants tested, 25 appeared to be targeted to NA as they showed a
positive HANA ELISA but a negative Western blot against rHA.
All 25 of these antibodies were tested, but only seven showed the ability to inhibit
NA activity in a Neuraminidase Inhibition (NI) assay (Figure 12). The NI assay allows us to
determine if an antibody (present in sera, in hybridoma supernatant, or as purified protein)
has the ability to inhibit the viral NA by measuring the enzymatic activity of NA in the
presence of antibody vs that of an uninhibited control. This is accomplished via colorimetric
assay which measures available N-acetyl neuraminic acid following incubation of antibody
(or control buffer), live virus, and NA substrate in the form supplemented of bovine fetuin
(93). Following overnight incubation, free N-acetyl neuraminic acid is measured by the
addition of arsenite and 2-Thiobarbituric Acid. The resulting hot pink color is then extracted
into the organic phase through the addition of Warrenoff reagent (acid butanol). Absorption
at 549 nanometers is determined using a fetuin blank to equilibrate the spectrophotometer.
NA enzymatic activity is shown normalized to an uninhibited virus control and experiments
were performed in duplicate. Supernatant from 2H9 secreting hybridoma cells, one of the
anti-HA antibodies developed by Dr Yu He, was used as a conditioned supernatant control.
It is likely the cellular supernatant contains sialic acid beyond the fetuin used in the assay,
thus explaining why supernatant containing mAb 2H9 shows NA activity above 100% when
normalized to the viral control. Supernatant containing mAb 2G5 (IgM) was the most
successful inhibitor of PR8 NA enzymatic activity followed by all three IgG candidates:
1G3, 2A7, and 1G9 (Figure 12).
Following primary screening via NI assay of hybridoma supernatants, the seven

41

mAb candidates from Immunization Protocol Alpha with NI activity were isotyped and
purified for further study (Table 2). MAb candidates were typed using a commercially
available isotyping cassette. IgG mAbs were then purified by Protein G column
chromatography. Concentrations were determined by Bradford assay and calculated from
the standard curve. Antibodies 1G3 and 1G9 originate from the same immunized mouse,
although the parent splenic B cell of each lineage is unique. 2A7 shares mouse origin and
parent cell with 1G9, although they are distinct clones from that line. It’s possible that 1G9
and 2A7 have the same epitope, but very unlikely 1G3 and 1G9 do.
IgG purification necessitates elution in a low pH solution that can compromise the
integrity and efficacy of an antibody. Therefore establishing NI activity following
purification is not only valuable in determining concentration dependence, but also in
establishing continued functional relevance. 2H9 is a PR8 specific anti-HA mAb developed
by Dr Yu He that binds the HA globular head and was selected as an antibody control. As
before, NA enzymatic activity is shown normalized to an uninhibited virus control and all
experiments were performed in duplicate. Where 2G5 (IgM) appeared the most successful in
supernatant, its NA inhibition was ablated following purification. It's unknown if this
reflects nonspecific inhibitors present in the cellular media or perhaps a loss of function
during the purification process. However all three of the IgG mAb containing conditioned
hybridoma supernatants which showed NA inhibition, 1G3, 2A7, and 1G9, continued to
inhibit PR8 NA once purified (Figure 13). Of these, 1G3 was the most efficient, followed
by mAbs 2A7 and 1G9. These data are indicative of the ability to interfere with the
enzymatic activity of NA. This can be attributed to one of two possible mechanisms, the first
being direct binding to NA. However, it has also been shown that some HA targeted
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antibodies can indirectly inhibit NA via steric hindrance (68).

We observed this

phenomenon experimentally with mAb 2H9. Despite its confirmed globular head/HA1
epitope, 2H9 was still was able to reduce PR8 NA activity by nearly 20% (Figure 13).
NA inhibition assays were then repeated in the presence of Triton X-100. The design
of this experiment was most recently outlined by Yewdell’s group (68) in an attempt to
distinguish true NA targeted antibodies vs HA antibodies which may also be able to inhibit
NA enzymatic activity. By solubilizing viral membranes, they aimed to spatially separate
HA and NA thus removing the contribution of steric hindrance. Their lab was able to use
this technique to show that the addition of Triton X-100 significantly lowers or completely
eliminates the ability of known HA antibodies to inhibit NA function measured by NI assay.
A/Puerto Rico/8/1934 (PR8, H1N1) suspended in infected allantoic fluid and 0.5% Triton
X-100 were co-incubated for 10 mins before the completion of the NI assay as described
previously. We performed this experiment with cloned hybridoma supernatant containing
antibodies 1G9 and 1G3 as well as with a 2H9 antibody control. Triton X-100 has been
shown to stabilize NA (13), and as expected it’s addition did increase NA activity in the PR8
control to above 100% relative activity of insolubilized virus. However, we found that the
addition of detergent eliminated NA inhibition by 1G3 and 1G9 previously seen. Triton
treatment also removed 2H9 mediated NA inhibition. (Figure 14).

According to the

hypothesis set forth by Yewdell et al, these data imply that 1G3 and 1G9 inhibit NA
indirectly.
The most well studied and common neutralizing antibodies to influenza A are those
like 2H9 and 2A6 which target the globular HA head. These antibodies prevent virus from
binding and entering the host cell during infection as well as prevent the HA mediated
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agglutination of red blood cells (102). In contrast, antibodies which target NA or the HA
stem have been shown to lack the ability to inhibit hemagglutination (69, 125). MAb 1G3
showed the most significant NI as a purified antibody (~50% reduction in NA activity in the
absence of detergent) and was next tested for its ability to inhibit the activity of the viral HA
head through a Hemagglutinin Inhibition (HAI) assay. Briefly, columns 1, 2, and 3 of a 96
well microtiter plate are loaded with antibody. Virus suspended in infected allantoic fluid at
an experimentally determined HA titer of 1:16 is then added to columns 2-12. Virus is not
added to column 1 to assess any possible nonspecific hemagglutination. Column 2 contains
virus with no antibody as a positive control for virus mediated agglutination. Starting in
column 3, purified antibody is serially diluted across the plate and an equal volume of 0.5%
chicken red blood cells is added to each well. While some viruses require the use of
alternative blood sources, like guinea pig or turkey, both PR8 and NYMC X-162 readily
agglutinate chicken red blood cells. Agglutination is seen as an opaque well while the
absence of agglutination is visualized by the pooling of red blood cells at the bottom of the
well, forming a “button” (64).
HAI assays were performed with purified 1G3 and 1G9 against both immunizing
viruses which carry different HA proteins; PR8 (H1N1) and NYMC X-162 (H3N1,
A/Wisconsin/67/2005 HA parent) (Figure 15). Experiments were performed twice, each in
duplicate. HA mediated agglutination of red blood cells was clearly seen in all columns 312, despite the presence of purified mAb 1G3 or 1G9 at concentrations as high has 1 mg/mL
in column 3. These data show that mAbs 1G3 and 1G9 cannot inhibit the agglutination of
red blood cells of either the H1 or H3 proteins and therefore likely does not bind to the
globular HA head.
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A second panel of hybridoma cell lines from an alternative immunization protocol were
also developed, referred to as Immunization Protocol Beta. HA is immunodominant in
natural and laboratory infections as well as following vaccination (80). Immunization
Protocol Beta (Figure 10) differs from Alpha in that HA+NA preparations were co-injected
with a mAb specific for PR8 HA, 2A6. 2A6 has been mapped by Dr Yu He to bind the HA
globular head of PR8. This protocol was designed with the intention of encouraging an
immune response to the PR8 NA, as HA would be theoretically occluded from immune
recognition due to the presence of bound 2A6. During Immunization Protocol Beta, sera on
Day 40 was collected for ELISA and for NA specificity testing via an NA inhibition assay.
Sera from all seven animals enrolled in Immunization Protocol Beta showed the ability to
inhibit PR8 NA (Figure 11). Fusions of splenic B cells from those animals with the most
significant ELISAs to generate hybridomas for further screening are currently ongoing.
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Figure 9: Immunization Protocol Alpha. N=8 female BALB/C mice (3 months old at D.0)
were immunized intraperitoneally first with A/Puerto Rico/8/1934 (PR8, H1N1) HA + NA
protein on days 0 and 14 followed by NYMC X-162 (H3N1, A/Wisconsin/67/2005 parent)
HA + NA protein preparation on day 28. Sera from immunized animals were screened by
ELISA against PR8 HA+NA on Day 40 and hybridoma fusions performed post intravenous
antigen boost and sacrifice on D.45. Image created with BioRender©
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Figure 10: Immunization Protocol Beta. N=7 female BALB/C mice (3 months old at D.0)
intraperitoneally immunized with A/Puerto Rico/8/1934(PR8, H1N1) and NYMC X-162
(H3N1, A/Wisconsin/67/2005 parent) HA+NA purified protein preparation co-injected with
PR8 HA head specific mAb 2A6 developed by Dr. Yu He. Sera were screened by ELISA on
Day 40 and hybridoma fusions performed post intravenous antigen boost and sacrifice on
D.45. Image created with BioRender©
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Figure 11: Relative neuraminidase Activity of sera collected from animals enrolled in
Immunization Protocol Beta (n=7). Sera from immunized animals was tested for the ability
to inhibit NA activity using a Neuraminidase Inhibition (NI) assay against both immunizing
viruses,
A/Puerto
Rico/8/1934(PR8,
H1N1)
and
NYMC
X-162
(H3N1,
A/Wisconsin/67/2005). NA Activity is shown relative to uninhibited viral controls. Sera from
each animal showed the ability to significantly inhibit the activity of NA of both PR8
(orange) and NYMC X-162 (red). Experiments performed in duplicate.
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Figure 12: Relative neuraminidase activity following incubation of A/Puerto
Rico/8/1934(PR8, H1N1) with seven antibody candidates developed from Immunization
Protocol Alpha as conditioned hybridoma supernatant. Data shown are relative to viral PR8
control and PR8 specific anti HA mAb 2H9 supernatant control. Supernatant from each of
seven hybridoma fusions negative for rHA binding by Western blot showed the ability to
inhibit the NA of PR8 by an average of 20%. Cellular supernatant likely contains additional
NA substrate above the supplemented fetuin, therefore the HA targeted 2H9 showed NA
activity above the viral control. Experiments performed in duplicate. * = p<0.05, ** =
p<0.01, *** = p<0.001
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Candidate
mAb

Isotype

2E9

IgM

3E9

IgM

1G3

IgG1

2A7

IgG1

1G9

IgG1

2G5

IgM

1D8

IgM

Table 2: Candidate monoclonal antibodies identified following Immunization Protocol
Alpha then subsequently purified. Antibodies shown failed to bind recombinant PR8 HA on
Western Blot but reacted with PR8 HA+NA protein by ELISA. Of seven antibody candidates,
four were of the IgM subclass while the remaining three were IgG1. 1G3, 2A7, and 1G9 are
from the same parental mouse. However 1G3 and 1G9 were derived from different parental
splenic B cells.
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Figure 13: Relative neuraminidase activity following incubation of virus and purified
antibody at a concentration of 1µg/mL, shown compared to viral PR8 (A/Puerto
Rico/8/1934, H1N1) control and anti-HA head mAb 2H9 antibody control. MAbs 1G3, 2A7,
and 1G9 (IgG1) each resulted in roughly a 50% reduction in NA enzymatic function. HA
targeted mAb 2H9 (IgG1) showed a reduction of almost 20% despite being targeted to the
HA head, likely due to steric hindrance. Experiments performed in duplicate. * = p<0.05,
** = p<0.01, *** = p<0.001
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Figure 14: Neuraminidase (NA) activity following incubation of virus and antibody
containing hybridoma supernatant shown relative to PR8 (A/Puerto Rico/8/1934, H1N1)
viral control. Virus suspended in allantoic fluid was pretreated with 0.5% Triton X-100
prior to assay to solubilize virion membranes. Triton has been shown to stabilize NA,
therefore an increase in NA activity was expected with the uninhibited PR8 virus control
treated with Triton. Antibodies 1G3 and 1G9 showed a reduction of roughly 40%, which
was completely reversed upon detergent treatment. 2A6 is an HA head targeted antibody
control, which again showed some inhibition of PR8 NA that was similarly ablated
following triton treatment. Experiments performed in quadruplicate. : * = p<0.05, ** =
p<0.01, *** = p<0.001
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Figure 15: Representative hemagglutination inhibition (HI) assay plate following
incubation of virus and purified 1G3 antibody with chicken red blood cells. Antibody
candidate 1G3 was tested at a high starting concentration of 1 mg/mL (column 3) and
serially diluted to column 12. Column 1 contains no virus as a negative control to assess
nonspecific agglutination. Column 2 contains no antibody as a positive control of
agglutination activity by the virus. Both immunizing viruses were tested, A/Puerto
Rico/8/1934 (PR8, H1N1, top rows) and NYMC X-162 (A/Wisconsin/67/2005 HA parent,
H3N1, bottom rows). Agglutination of the red blood cells by both viruses was seen in all
rows of columns 2-12, demonstrating that mAb 1G3 lacks the ability to inhibit either the H1
or H3 HA head.
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Aim 2. Characterize binding profile and epitope of candidate mAbs
Candidate mAb 1G3 is an IgG1 antibody that displayed an interesting activity profile
in our primary screen. 1G3 showed NA inhibition in an NI assay (Figures 12, 13) which is
indicative of an antibody that can block NA enzymatic function. However, 1G3 lacked NA
inhibition activity following virus pre-treatment with detergent (Figure 14) and additionally
lacked the ability to inhibit HA head mediated agglutination (Figure 15). These data
together suggest an epitope outside of NA and away from the HA head, possibly on the HA
stem. In order to confirm mAb 1G3’s viral target, Western blots were performed.
First, commercially available recombinant A/Puerto Rico/8/1934 HA H1 (PR8,
H1N1)

(rHA)

as

well

as

both

immunizing

viruses

NYMC

X-162

(H3N1,

A/Wisconsin/67/2005 HA parent), and native PR8 (H1N1) as infected allantoic fluid were
run on a 4-12% gradient Bis Tris gel in non-reducing conditions (Figure 16). MAb 1G3
containing conditioned hybridoma supernatant was used as the primary probing antibody at
a dilution of 1:128,000. An infrared goat anti-mouse secondary was incubated with the
membranes and all blots were visualized using an Odyssey Scanner. Candidate mAb 1G3
showed the ability to bind both NYMC X-162 and native PR8. Bands were seen at roughly
70, 125 and 260 kDA for PR8 and 85, 100, and 130 kDA for NYMC X-162. When repeated
in reducing conditions, a faint band could also be seen around 25 kDa for both immunizing
viruses in addition to a larger, significant band between 55 and 75 kDa (Figure 17). In both
reducing and non-reducing conditions, 1G3 was not able to bind to the recombinant PR8 HA
H1 subunit despite displaying excellent affinity for native PR8 in allantoic fluid.
MAb 2A6 containing hybridoma supernatant was used as the primary probing
antibody as a blotting control. 2A6 is a PR8 specific anti-HA head antibody previously
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identified by Dr Yu He. 2A6 showed excellent affinity for native PR8 in non-reducing
conditions, with a band visible at roughly 70 kDa (Figure 16). 2A6 produced no bands in
reducing conditions (Figure 17).
The band pattern on the 1G3 probed blot was consistent with what was seen when
probing with anti-HA mAb 2A6 – both produced a major signal at roughly 70 kDA for PR8.
2A6 has been mapped to bind HA1, the larger component of the HA0 monomer. We
therefore hypothesized that 1G3 also bound HA, not NA, consistent with what we observed
in the primary screen. HA in infected allantoic fluid exists as cleaved HA1 and HA2
subunits, the uncleaved HA0 monomer, and the functional HA trimeric unit. We conjectured
that the bands seen on 1G3 probed non-reducing blot corresponded to HA1, HA0 monomer,
the HA trimer, as well as heavy oligomeric forms at the top of each well.
In reducing conditions, mAb 1G3 produced a significant band at roughly 55 kDa for
PR8 (H1N1) and very near to 70 kDa for NYMC X-162 (H3N1), as well as a faint second
band at 25 kDa for each (Figure 17). For PR8 (H1N1), these two bands match known
molecular weights for glycosylated HA1 and HA2, the two peptide components of the
cleaved monomer that in reducing conditions are resolved into two bands (117). However,
the slightly larger molecular weight for the dominant band observed for NYMC X-162
(H3N1) could be as a result of increased glycosylation on H3 or because mAb 1G3 is
binding uncleaved HA0 present in the fluid. It is important to note that the size of HA seen
on Western blots varies greatly between virus subtypes as a result of major differences in
glycosylation patterns (63, 132).
The non-reducing and reducing blots taken together with comparison to the 2A6
control bands make an NA target for mAb 1G3 unlikely. The influenza NA monomer has a
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smaller molecular weight of roughly 60 kDa in non-reducing conditions but can form higher
molecular weight oligomers. However, NA is a single polypeptide lacking distinct subunits
and does not separate into separate bands in reducing conditions (104).
Molecular weights and banding patterns corresponding to HA were initially
surprising, as PR8 (H1N1) and NYMC X-162 (H3N1) share an NA protein but differ in
their HA components. NYMC X-162 is a 7:1 reassortant virus, meaning it has all PR8 genes
except the HA which is derived from A/Wisconsin/67/2005 (H3N2). The HA head is
extraordinarily immunodominant in natural and laboratory infections and these head
antibodies are characterized by strict strain specificity (82). However, these blots would
appear to suggest that 1G3 was binding both H1 (group 1 IAV) and H3 (group 2 IAV). We
next performed a series of several Western blots to confirm the unique heterosubtypic
binding character of mAb 1G3. MAb 1G3 was first tested against the NYMC X-162 wild
type HA parent, A/Wisconsin/67/2005. We also tested the ability of 1G3 to bind
A/California/07/2009, which is a pandemic H1N1 virus still circulating in people and the
causative virus of the 2009 “Swine Flu” (73). MAb 1G3 successfully bound each of these
viruses at a molecular weight corresponding with HA, despite the fact they each carry a
different HA protein (Figure 18). The banding pattern observed was similar as in the
previous

reducing

blot,

however

neither

A/California/07/2009

(H1N1pdm)

nor

A/Wisconsin/67/2005 (H3N2) appeared to show the second lower weight molecular band.
Candidate mAb 1G3 thus far has shown the ability to recognize various putative HA
targets, including wild type H1, H1 pandemic, and H3 viruses in addition to an H3
reassortant virus, which represent members of both Groups 1 and 2 influenza A viruses.
Because HA is known to drift significantly over time, we were interested to determine if this
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broadly binding character was limited temporally to relatively recently emerged viruses or if
1G3 was capable of binding H1 and H3 viruses from decades past.
We used mAb 1G3 to probe two additional H1N1 viruses of non-pandemic lineage,
A/Hong Kong/50/2014 and A/New Caledonia/20/1999. We also tested two additional H3N2
viruses, A/South Dakota/06/2009 and A/Moscow/10/1999. Viruses were chosen to be
representative of circulating wild type viruses from both H1 and H3 subtypes (Groups 1 and
2 respectively) over the last two decades. This is in addition to previously tested immunizing
virus PR8, which was isolated in 1934. We also elected to include two influenza B viruses,
B/Massachusetts/02/2012 (Yamagata) and B/Brisbane/60/2008 (Victoria). These are both
wild type viruses, representing the two major lineages of influenza B viruses. Using
uninfected allantoic fluid as a protein background control, we found that mAb 1G3 was able
to successfully bind all viruses tested (Figure 19). Each virus, including both influenza B
strains, showed a strong band at roughly 70 kDa, consistent with previous blots. A/South
Dakota/06/2007 also showed the second smaller band at roughly 25 kDa that was observed
with PR8 and NYMC X-162.
These results were startling, as a mAb that can bind multiple viruses not only within
a subtype but across IAV groups is a relatively rare occurrence. There are roughly of dozen
of these cross reactive antibodies in the literature, some isolated from isolated patients and
some developed following successive immunization of animals with multiple HA subtypes
(29, 121, 140). An antibody that can bind both influenza A and influenza B is the rarest of
influenza antibodies. To date, there is one antibody published and recently patented that can
inhibit both influenza A and B in vivo, CR9114 (32).
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Despite not binding to uninfected allantoic fluid, we next assessed the possibility that
the 1G3 epitope in part or in whole consisted of glycan motifs. An antibody to sugar motifs
may be able to bind a wide range of viruses, but would negate its relevance as a reagent, as a
means of epitope discovery, or as a potential treatment modality. Previous isotyping of 1G3
described in Specific Aim 1 revealed it to be IgG1, making an entirely glycan epitope
unlikely as class switching from IgM to IgG had occurred in the immunized mouse. Class
switching in a murine model, as in humans, is most often as a result of protein stimulation
(30). In order to establish the molecular character of the epitope target, we decided to treat
previously blotted

viruses

PR8

(H1N1),

A/California/07/2009

(H1N1pdm),

and

A/Wisconsin/67/2005 (H3N2) with PNGase F. PNGase F is commercially available enzyme
purified from Flavobacterium meningosepticum that cleaves N-linked glyco-motifs from
protein (72, 116). Subsequent to overnight enzyme treatment of infected allantoic fluid,
mAb 1G3 was still capable of binding each virus, but with diminished affinity (Figure 20).
These data supported our hypothesis that the 1G3 epitope is modulated by glycan, either by
direct binding to some critical carbohydrates or most likely to a conformational epitope
supported by glycan scaffolding. However, because the signal was indeed present after
enzyme treatment these data also demonstrate that the epitope is not entirely composed of
sugars and 1G3 does in fact interact with amino acids of HA. Candidate mAb 1G3 thus far
was shown to bind wild type and reassortant H1, H1pdm H3, and B viruses (from both
lineages) spanning the last 20 years. The 1G3 epitope was not present in uninfected allantoic
fluid and was not dependent on glycans alone.
In order to confirm candidate mAb 1G3 was indeed binding the viral HA target and
not a identically sized protein present as a result of propagation in eggs, we next performed a
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series of blots with purified HA+NA from PR8 as well as whole purified virus NYMC X187 and HA+NA from NYMC X-179A. Both NYMC X-187 and NYMC X-179A are high
yield reassortant viruses prepared via classical reassortment by Jean Marie Silverman and
Barbara Pokorny in our lab as candidate vaccine seeds. NYMC X-187 is an H3N2 virus with
HA and NA genes from A/Victoria/201/2009 and six internal genes of PR8. NYMC X-179A
is an H1N1pdm virus with the HA, NA, and PB1 genes of A/California/07/2009 and the five
remaining genes from PR8.
Virus purification is a multistep process that begins with amplifying and harvesting
virus from infected embryonated chicken eggs. Allantoic fluid was pooled and spun to
remove cellular debris, and then centrifuged at high speed in an ultracentrifuge to pellet
virus. Finally, the viruses were purified using a sucrose gradient whereby virus collects at
the 30%-60% interface. This solution was again centrifuged at high speed (20,000 rpm)
before being soaked overnight in a calcium containing buffer to maintain the structural and
enzymatic integrity of HA and NA (13). Viral protein content was measured by a standard
Lowry assay.
First, 10 µg of each purified virus or viral HA+NA were blotted in non-reducing
conditions with 50 µg purified Bovine Serum Albumin (BSA, Sigma) as a binding control.
As anticipated from previous blots, mAb 1G3 bound purified PR8 (H1N1) HA+NA, NYMC
X-187 (H3N2), and NYMC X-179A (H1N1pdm) HA+NA, but not the BSA control. PR8
specific anti-HA mAb 2A6 only bound purified PR8 (H1N1) HA+NA, failing to bind the
other HA subtypes and the BSA control (Figure 21). This blot was repeated using 1 µg of
each purified virus to prevent overexposure. Purified ovalbumin was used as an additional
binding control. Consistent with blots done from allantoic fluid, major bands were seen at
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roughly 55 kDa for the H1 and H1pdm viruses (PR8, NYMC X-179A) and 70 kDa for the
H3 virus (NYMC X-187) in reducing conditions. Additionally, both the H1 and H1pdm
viruses showed the second putative HA2 band at 25 kDa. No binding to either control (BSA
or ovalbumin) was observed despite high protein load (Figure 22). This blot was repeated
using PR8 specific anti-HA mAb 2A6 as the primary antibody control with ovalbumin as a
protein binding control. As expected, major banding was only observed for purified PR8
HA+NA in non-reducing conditions (Figure 23). Again, it was observed that the banding
pattern for PR8 was identical either with known HA antibody 2A6 and our candidate 1G3.
We also observed that in reducing conditions bands produced with 1G3 were of
diminished intensity compared to equivalent blots in non-reducing conditions. This is a
pattern commonly associated with discontinuous epitopes, contrasted with linear epitopes
wherein binding should produce an identical signal regardless of protein shape (45, 61).
While conventional wisdom held that antibodies used to probe Western blots could only
recognize linear epitopes, it has since been established that some proteins may undergo
renaturation following transfer. Therefore positive results on a Western blot, especially
when signal is diminished by reduction, can also be indicative of recognition of a
discontinuous or conformational epitope (143).
By using purified virus or viral protein devoid of cellular or host derived debris, we
were able to confirm a unique pattern where the major band from both H1 and H1pdm
viruses appeared to be of lower molecular weight than that seen with the H3 virus (70 kDa
vs 50 kDa). This could be as a result of increased glycosylation of the H3 virus making the
HA heavier, or because mAb 1G3 binds HA1 of H1 viruses and the larger HA0 monomer of
H3 viruses. We hypothesized that the 1G3 epitope lies on HA1 subunit, but the 3D
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conformation necessary for binding is only present in the HA0 monomer of H3 viruses. In
order to test this hypothesis, the same three purified viruses were subject to overnight
treatment with trypsin to cleave any HA0 monomers present in solution and then blotted in
reducing conditions to resolve all HA0 into its two subunits, HA1 and HA2. NYMC X-187
(H3N2) treated with trypsin could no longer be bound by 1G3 while PR8 HANA (H1N1)
and NYMC X-179A (H1N1pdm) retained identical banding pattern (Figure 24). These data
support that the 1G3 target epitope is slightly altered for the H3 viruses, as was suggested by
differences in banding weight. This also suggests that although the epitope is retained in
reducing conditions, it is dependent on conformation of the HA subunits as we suspected
from the observed decrease in affinity following reduction or the removal of glycans by
PNGase F.
As another approach to confirming a shared HA epitope as the target of 1G3, next
decided to test a panel of recombinant HA proteins. Previously we had demonstrated that
mAb 1G3 did not bind recombinant PR8 H1 HA. However, the PR8 specific 2A6 antibody
also showed low affinity in Western blot and we suspected that recombinant protein may
have been compromised in storage (Figure 16). Additionally, we tested a recombinant HA
from A/Perth/16/2009 (H3) as well as A/Vietnam/1194/2004 (H5). The recombinant protein
from A/Perth/16/2009 (H3) was sourced from baculoviral cells and was not full length,
instead encoding only the HA1 domain. Binding would demonstrate not only that 1G3 could
bind this particular H3 virus, but that it bound the glycosylated HA1 subunit as opposed to
the H3 HA0 monomer as we suspected was the case from the trypsin blots.
A/Vietnam/1194/2004 is an H5 virus and is a Biosafety Level 3 highly pathogenic avian
influenza (HPAI) (3, 99). Its HA component alone as a recombinant protein can be used at
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BSL-1 for Western blotting, allowing us the opportunity to test this previously untested HA
subtype. Both the recombinant HA from PR8 (H1) and A/Vietnam/1194/2004 (H5) were the
extracellular domains secreted from HEK293 cells. MAb 1G3 was not able to bind these
recombinant proteins in reducing or non-reducing conditions (Figure 25), despite previously
binding PR8 in allantoic fluid and as purified protein. This is most likely explained by the
baculoviral or HEK293 cell systems being incapable of maintaining proper shape for 1G3
binding, either in terms of epitope fidelity or 3D conformation. It’s also possible that either
as only HA1 or only the extracellular domain, there are amino acids in the membrane
proximal portion of the HA stem that were missing or incomplete. Finally, it’s also possible
that as recombinant proteins they are not available in the active HA trimer formation, which
may be necessary for 1G3 binding. While recombinant proteins are useful, they have been
cited as poor antibody validation tools (12, 128).
While we previously established that the 1G3 epitope is not glycan alone, next we
chose to test two control viruses for 1G3 binding: Sendai Virus and Respiratory Syncytial
Virus (RSV). The Paramyxovirus group includes parainfluenza viruses (Sendai),
Metapneumonia virus, and RSV. These viruses are responsible for a growing number of
hospitalizations in the United States, especially among children and elderly. Often these
infections are misdiagnosed as influenza, as symptoms are largely overlapping (21, 110).
Paramyxoviruses are closely related to Orthomyxoviruses. Like influenza, RSV and Sendai
are enveloped viruses with a single stranded negative sense RNA genome. However, unlike
flu their genomes are contiguous and undergo replication in the cytoplasm of infected cells
(37). While Sendai virus does not infect humans, it is often used as an animal model for
human parainfluenza infections. Sendai is a well-documented agricultural blight, as it can
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cause death in chicken stocks (78). Because mAb 1G3 failed to bind any of the recombinant
proteins tested, we analyzed Sendai and RSV as sucrose gradient purified native protein.
The Sendai virus used was amplified in the same eggs from the same distributor we use
internally for influenza, allowing it to serve as a control for egg propagation effects in
addition to a binding control as a closely related virus. 1G3 did not bind native RSV or
Sendai in either reducing or non-reducing conditions (Figure 26).
These blots suggest that candidate mAb 1G3 is a unique antibody that can bind HA
of H1, H1 pandemic, and H3 viruses of influenza A as well as the HA of two distinct
lineages of influenza B viruses. Banding pattern and molecular weight analysis suggests that
the epitope of 1G3 is conformational and lies predominantly on HA1, as each virus tested
shows a high molecular weight band between 70 and 80 kDA. However at least a part of the
epitope may be found on HA2 for some viruses, observable as a second lower molecular
weight band at 25 kDa. Trypsin cleavage ablates the consensus sequence for H3 virus
NYMC X-187, implying that some part of the antibody footprint lies in or around the
HA1/HA2 cleavage site located at the C terminal end of HA1. It's also possible that cleavage
disrupts necessary conformation for H3 binding, but not H1 binding. Interestingly, mAb
1G3 was not able to bind any recombinant proteins; further supporting a conformational
epitope that may not be easily recapitulated by non-native protein. Blot results are
summarized in Figure 27.
To investigate whether there was any apparent sequence homology between
heterosubtypic viruses at this predicted HA1/HA2 epitope, we completed an in silico
sequence alignment of the HA segments of A/Puerto Rico/8/1934 (PR8, H1N1, ID
CY045764), A/California/07/2009 (H1N1pdm, ID CY121680) and A/Victoria/201/2008
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(H3N2, ID KM821344). Analysis was performed using sequences from the NCBI Influenza
Database using LaserGene Suit MegAlign software following alignment by Clustal W
method.
We observed that these three viruses share significant homology centered about the
HA1/HA2 cleavage site despite their different IAV grouping (Figure 28). This is
unsurprising, as every wild type IAV HA subtype (with the exception of HA14) share the
same P4-P1 sequence for recognition by trypsin-like proteases in the host. Cleavage
consistently occurs at the same invariant arginine residue shared by nearly every influenza
virus, including these three (109). Only HPAI viruses, which contain a multibasic cleavage
site, differ (112). The fusion peptide at the N terminal region of HA2 is one of the most
highly conserved peptide sequences across all influenza viruses, however our blotting data
suggested the majority of the 1G3 epitope is on the HA1 peptide as only some viruses
displayed the lower molecular weight HA2 band. While sequence hormonology around and
upstream of the cleavage site present on HA1 is encouraging, most epitopes are not
continuous. It’s likely that the true epitope of mAb 1G3 is dependent on the conformation of
the C terminal domain of HA1 both in the context of the monomer and as a resolved subunit.
Epitope mapping of mAb 1G3 against PR8 HA was completed by PEPperPRINT via
PEPperMAP® linear epitope mapping using a peptide microarray chip. The sequence of
A/Puerto Rico/8/1934 (ID B4UPA6) HA was submitted and elongated with neutral linkers
(GSGSGSG) at both the N and C termini to prevent truncated peptides. The sequence was
then translated into 15 amino acid peptides with an overlap of 14 amino acids, yielding 565
unique peptides printed in duplicate (Appendix 2: Peptide Map). Unlike similar
technologies, peptides were synthesized directly unto the chip to eliminate the need for
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immobilization. Between different printing steps, “amino acid toners” were melted to release
amino acids and initiate synthesis. Following washing, the N-terminal Fmoc group was
unprotected to allow for the next round of toners to be printed and coupled. Control c-myc
(EQKLISEEDL) peptides were spotted along the perimeter of the chip. The chip was then
incubated with purified 1G3 at concentrations of 10 µg/mL and 100 µg/mL and stained with
a DyLight 680 goat anti-mouse secondary before being scanned with a LI-COR Odyssey
Imaging System. Quantification of spot intensities was done with a proprietary software,
PepSlide® Analyzer.
Following analysis, peaks of fluorescence associated with binding failed to reach
statistical significance. This is mostly likely attributed to our conformational epitope being
analyzed by a software program which is designed to detect linear binding. Linear binding is
seen as peaks of neighboring peptides in a tight bell curve centered on the epitope, as
opposed to several distinct peaks along the protein as we observed. However, the raw data
provides some valuable insight into a proposed 1G3 epitope. At both 10 and 100 µg/mL,
1G3 showed nine significant peaks in fluorescent intensity (Figure 29). There was perfect
agreement regarding the location of these peaks between the two concentrations. Two of
these, corresponding with peptides LSSVSSFERFEIFPK and GKEVLVLWGIHHPSN, fall
in the receptor binding domain and are unlikely to be involved in the neutralizing
mechanism of 1G3 in context with the lack of observed HA inhibition activity. However,
two of the remaining seven peaks were consistent with our predicted epitope based on
Western blotting and in silico analysis. Peptides PVTIGECPKYVRSAKL and
YAADQKSTQNAINGIT fall at the C terminus of HA1 and N terminus of HA2 within the
fusion peptide sequence, straddling the protease cleavage site (Figure 30). These epitopes
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were visualized on the HA HA) monomer and active HA trimer using iCn3D, a web-based
protein structure viewer hosted by NCBI (Figure 31). These peaks tracked to the HA stem,
sitting below the globular head and surrounding the fusion peptide located on the interior of
the trimer.
The predicted 1G3 epitope was then compared with the published epitopes of
previously identified broadly neutralizing stem antibodies: CR9114 (32), F16 (14), C05
(36), and C179 (85). While we were limited to 15 amino acid peptide sequences, epitopes of
these other antibodies have been established to a single amino acid resolution using X-ray
crystallography. Our epitope appeared to correspond remarkably well with two known HA
stem antibodies, CR9114 and C179 (Figure 30). CR9114 is the only published antibody that
can protect mice from lethal challenge of both groups of influenza A as well as both lineages
of influenza B (32). C179 was discovered in 1993 and is the first antibody identified that
could neutralize multiple subtypes of influenza A, however only within Group 1 (85). While
their epitopes are similar, and in fact overlap at several positions, the binding of C179 is
rotated 45° from CR9114. Interestingly, C179 has a similar approach angle to the
epitopically distinct F16 which targets the protease recognition site. It has been
experimentally determined that group and subtype specific differences at amino acid
position 111 of HA2 prevent C179 from binding Group 2 IAV (31). While Group 1, like
A/Puerto Rico/8/1934 (H1N1), feature a histidine; Group 2 strains instead code for threonine
or alanine. This results in a subtly different conformation of an indole side chain located at
position 21 on HA2 that prevents interaction with a phenylalanine at the tip of the heavy
chain complementarity determining region 3 of C179. Mutating His111Thr on HA2
abrogated C179 binding and underlies its inability to bind Group 2 viruses (31, 66, 85). We
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hypothesize that because of the more broadly neutralizing character of 1G3, its angle of
approach is likely more similar to CR9114 which is unaffected by an amino acid change at
position 111. Both Cr9114 and C157 antibodies target the HA fusion peptide located in the
stem domain. Functionally, they prevent low pH induced conformational changes to
HA1/HA2 necessary for release of the virion into the cytoplasm in vitro (22, 115, 137).
While the linear peptide mapping was performed with the HA sequence of A/Puerto
Rico/8/1934, we also saw that 1G3 can efficiently bind to heterologous viruses. In order to
identify any specific amino acids that may be major contributors to the epitope, we
performed a sequence alignment of PR8 (H1N1), A/Hong Kong/4801/2014 (H3N2) and
B/Brisbane/60/2008 (Victoria) (Figure 32). Interestingly, over half of the amino acids in the
proposed 1G3 binding site were conserved between these three very distinct influenza
viruses, 16 out of 30 residues in total. This demonstrates that although these viruses
represent both groups of influenza A as well as influenza B, there is significant conservation
in the stem that can be exploited for broad neutralizing potential.
Antibody candidate 1G3 has a conformational epitope that may lie at the C terminal
region of HA1 and the N terminal region of HA2. It appears to share many amino acids with
the published epitopes of similarly broadly neutralizing stem targeted antibodies, like
CR9114 and C179. However, mAb 1G3 is a unique antibody that is epitopically similar to
both C179 and CR9114, sharing amino acids in both HA1 and HA2 footprints, but like
CR9114 is able to bind both groups of influenza A as well as influenza B.
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Figure 16: Non-reducing Western blot of Recombinant A/Puerto Rico/8/1934 HA (PR8,
rHA, H1), NYMC X-162 (H3N1, A/Wisconsin/67/2005 HA parent) and native PR8 (H1N1)
in allantoic fluid. 1G3 (left) or anti-H1 HA head antibody 2A6 (right) containing hybridoma
supernatant was used as primary antibody and an infrared goat anti mouse secondary was
used to visualize bands. Each lane was loaded with 20 µL infected allantoic fluid or 0.1 µg
rHA as noted. 1G3 successfully bound both PR8 and X-162 to the exclusion of recombinant
PR8 H1 HA.
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Figure 17: Reducing Western blot of Recombinant A/Puerto Rico/8/1934 HA (PR8, rHA,
H1), NYMC X-162 (H3N1, A/Wisconsin/67/2005 HA parent) and native PR8 (H1N1) in
allantoic fluid. 1G3 (left) or anti-H1 mAb 2A6 (right) containing hybridoma supernatant
was used as primary antibody and an infrared goat anti mouse secondary was used to
visualize bands. Each lane was loaded with 20 µL infected allantoic fluid or 0.1 µg rHA.
Where 2A6 does not bind in reducing conditions, 1G3 bound native PR8 and X-162 with
both a high (60-70 kDA) and lower (25 kDA) molecular weight band.

69

Figure
18:
Reducing
Western
blot
of
A/California/07/09(H1N1pdm),
A/Wisconsin/67/05(H3N2), and A/Puerto Rico/8/1934 (PR8, H1N1) in allantoic fluid using
1G3 (left) or anti-H1 HA mAb 2A6 (right) containing hybridoma supernatant as primary
antibody. An infrared goat anti mouse secondary was used to visualize bands. Each lane
was loaded with 10 µL infected allantoic fluid. 1G3 successfully bound the H1, H1pdm, and
H3 wild type viruses.
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Figure 19: Reducing Western blot of two H3N2, two H1N1, and two influenza B viruses in
allantoic fluid. Viruses from left to right (lanes 1-8): A/Hong Kong/50/2014 (H3N2),
A/Moscow/10/1999 (H3N2), A/New Caledonia/20/1999 (H1N1), A/South Dakota/06/2007
(H1N1), B/Brisbane/60/2008 (Victoria), B/Massachusetts/02/2012 (Yamagata Lineage).
MAb 1G3 containing hybridoma supernatant was used as primary antibody and an infrared
goat anti mouse as the secondary to visualize bands. 1G3 bound both the influenza A and
influenza B viruses tested, despite varying HA proteins across subtype, group, and lineage.
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Figure 20: Non-reducing Western blot A/Puerto Rico/8/1934 (PR8,H1N1),
A/California/07/2009 (H1N1pdm), and A/Wisconsin/67/2005(H3N2) using 1G3 containing
hybridoma supernatant as primary antibody and an infrared goat anti mouse as the
secondary to visualize bands. Each lane was loaded with 20 µL infected allantoic fluid. Left
panel shows virus treated with a buffer control while viruses in lanes 5, 6, and 7 were
treated with PNGase F, an enzyme that removes N-linked glycosylation. All viruses were
incubated overnight at 37°C prior to blotting. While affinity was lower, 1G3 still bound
viruses devoid of sugar groups.
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Figure 21: Non-reducing Western blot of purified A/Puerto Rico/8/1934 (PR8, H1N1)
HANA, NYMC X-187 (H3N2), and NYMC X-179A (H1N1pdm) HANA. MAb candidate 1G3
(left) or anti-PR8 HA 2A6 (right) containing hybridoma supernatant were used as primary
antibodies followed by an infrared goat anti mouse secondary to visualize bands. Each lane
was loaded with 10 µg purified virus/viral protein or bovine serum albumin control (lanes 4
and 9). 1G3 successfully bound virus purified from egg protein. Blue signal is an artifact of
overexposure during membrane scanning.
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Figure 22: Non-reducing (left) and reducing (right) Western blot with purified A/Puerto
Rico/8/1934 (PR8, H1N1) HANA, NYMC X-187(H3N2), and NYMC X-179A (H1N1pdm)
HANA using 1G3 hybridoma supernatant as primary antibody, followed by an infrared goat
anti mouse secondary to visualize bands. Each lane was loaded with 1 µg purified viral
protein or 80 µg Ovalbumin control.
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Figure 23: Non-reducing (left) and reducing (right) Western blot with purified A/Puerto
Rico/8/1934 (PR8, H1N1) HANA, NYMC X-187(H3N2), and NYMC X-179A (H1N1pdm)
HANA using PR8 specific anti-HA 2A6 hybridoma supernatant as primary antibody,
followed by an infrared goat anti mouse secondary to visualize bands. Each lane was loaded
with 1 µg purified viral protein or 80 µg Ovalbumin control. Unlike 1G3, blotting control
2A6 did not show hetero-HA reactivity.

75

Figure 24: Reducing Western blot of purified A/Puerto Rico/8/1934 (PR8, H1N1) HANA,
NYMC X-187 (H3N2), and NYMC X-179A (H1N1pdm) HANA. MAb candidate 1G3
containing hybridoma supernatant was used as primary antibody followed by an infrared
goat anti mouse secondary to visualize bands. Each lane was loaded with 1 µg purified virus
or viral protein. Lanes 1, 2 and 3 were subject to a buffer control while lanes 5, 6 and 7
were treated with trypsin. Trypsin cleavage removes HA0 monomers present in the sample,
leaving only HA1 and HA2. All samples were incubated overnight at 37°C prior to blot. 1G3
was no longer able to bind H3N2 virus following treatment with trypsin.
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Figure 25: Non-reducing (left) and reducing (right) Western blot using recombinant HA
(rHA) proteins from A/Puerto Rico/8/1934 (PR8, H1), A/Perth/16/2009 (H3) and
A/Vietnam/1194/2004 (H5). Recombinant PR8 and A/Vietnam HA consists of the secreted
extracellular domain and was isolated from HEK293 cells. Recombinant A/Perth HA
consists of only the HA1 domain and was isolated from a baculoviral system. MAb
candidate 1G3 containing hybridoma supernatant was used as primary antibody followed by
an infrared goat anti mouse secondary to visualize bands. Each lane was loaded with 1 µg
recombinant viral protein. 1G3 successfully bound purified native PR8 protein but showed
no reactivity with any recombinant HA.

77

Figure 26: Non-reducing (left) and reducing (right) Western blot using sucrose gradient
purified antigen from Sendai and Respiratory Syncytial Virus as well as an uninfected
allantoic fluid control. MAb candidate 1G3 containing hybridoma supernatant was used as
primary antibody followed by an infrared goat anti mouse secondary to visualize bands.
Each lane was loaded with 1 µg viral protein. 1G3 successfully bound native PR8 to the
exclusion of the closely related Sendai and Respiratory Syncytial viruses. 1G3 showed no
reactivity for allantoic fluid alone.
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Figure 27: Summary of Western blot results. Viruses in the green circle showed an HA0 or
HA1 band between 60 – 80 kDa in both reducing and non-reducing conditions. Those listed
in the nested pink circle showed an HA0 or HA1 band plus an additional HA2 band at ~25
kDa in reducing conditions. MAb 1G3 was not able to bind controls in italics as well as
recombinant proteins listed in the red circle. Control viruses Sendai and RSV were tested as
purified whole virus, not recombinant proteins.
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Figure 28: Sequence alignment of the HA segments of PR8 (H1N1, HA-CY045764, top
row), A/Victoria/201/2008 (H3N2, KM821344, middle row), and A/California/07/2009
(H1N1pdm, CY121680, bottom row). Box highlights the P4-P1 loci of the trypsin cleavage
site. Red dotted line delineates HA1 and HA2 where HA2 N terminus begins with consensus
sequence G-L/I-F. Blue highlight shows amino acids where H1 and H1pdm viruses agree to
the exclusion of the H3 virus. Gold highlights amino acids where all three viruses diverge.
Generally, the area of highest conservation lies around the fusion peptide downstream of the
trypsin recognition sequence.
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Figure 29: 15 amino acid peptides with 14 amino acid overlaps were generated from the
HA sequence of A/Puerto Rico/8/1934 and synthesized directly on to a PEPperMap linear
peptide array. Fluorescent intensity measured in arbitrary units (a.u.) following peptide
chip incubation with mAb 1G3 at a concentration of 10 and 100 µg/mL and a fluorescent
secondary antibody. Where a linear epitope would appear as a bell curve around a single
sequence, we observed 9 distinct peaks along the length of the HA protein. Full peptide map
can be found in the appendix.
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Figure 30: HA amino acid sequence of A/Puerto Rico/8/1934 (UniProt ID B4UPA6).
Binding peaks of 1G3 from epitope mapping are shown in the top row in purple. Epitope
sequences of known HA stem antibodies determined by X-ray crystallography (bottom row)
are noted in blue for CR9114 and pink for C179. GLF, highlighted in yellow, are the first
amino acids at the N terminus of HA2.
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Figure 31: 3D visualization of A/Puerto Rico/8/1934 HA with predicted 1G3 epitope via
iCn3D. A: HA monomer with HA1 in magenta and HA2 in blue. Portions of predicted 1G3
epitopes PVTIGECPKYVRSAKL and YAADQKSTQNAINGIT are highlighted in cyan on the
HA stem. B: HA trimer with HA protein in magenta, predicted 1G3 epitopes in blue, and the
linker sequence of the HA fusion peptide in cyan on the interior of the HA trimer. Sialic acid
interactions at the receptor binding head are shown in green.
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Figure 32: HA amino acid sequence of A/Hong Kong/4801/2014 (top) and
B/Brisbane/60/2008 (bottom). The two putative binding sites of 1G3 of interest are
underlined and bolded. Amino acids within that footprint which are conserved between
A/Puerto Rico/8/1934 as well as A/Hong Kong/4801/2014 and B/Brisbane/60/2008 are
highlighted in cyan. GLFGAIA, highlighted in yellow, are the first amino acids of the N
terminus of the HA2 subunit.

84

Aim 3. Evaluate candidate mAbs efficacy in vitro and in ovo
Despite the breadth of viral subtypes bound by mAb 1G3 on Western blot,
interaction with a viral target does not necessarily translate to inhibition or neutralization of
virus during an infection. In order to assess mAb 1G3’s ability to inhibit virus replication we
performed Plaque Reduction and Neutralization Tests (PRNTs) coupled with fluorescence
microscopy in vitro as well as time course inhibition assays in ovo.
PRNTs are complementary to previously described NI and HAI assays in that they
measure the functional impact of mAb 1G3 on virus. Where NI and HAI assays quantify
effect on viral protein, PRNTs instead look only at live, actively replicating virus. Madin
Darby Canine Kidney (MDCK) cells were seeded into a 6-well plate and allowed to reach
80-90% confluency. Following 30 mins of viral exposure, inoculum is removed and an
oxoid agar overlay applied. The overlay itself serves several chemical and physical roles in
propagating infection. MDCK cells do not possess the necessary cellular proteases for
productive influenza replication (4, 66). HA on the virion surface must be cleaved into its
active subunits HA1 and HA2 to allow for entry into the cell as well as exit from the
endosomal compartment (10, 42, 112). Therefore, the overlay contains TPCK treated free
trypsin to ensure budding virions display mature HA and are infection competent. The
overlay also serves to restrict virus to lateral movement to adjacent cells following the initial
infection while allowing cells to participate in oxygen exchange. Resulting localized foci of
cell death and detachment are known as “plaques”. 1G3 was applied in the overlay media as
purified mAb and also Receptor Destroying Enzyme (RDE) treated hybridoma conditioned
supernatant. RDE is a commercially available enzyme purified from Vibrio cholerae that
works to eliminate any non-specific inhibitors of viral replication that may be present in the
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supernatant (60, 65). 72 hours post infection the overlay is removed and plaques visualized
with 0.1% crystal violet in 20% ethanol to fix and stain what remains of the surviving
cellular monolayer.
Initially, all seven candidate monoclonal antibodies with positive NI were screened
for plaque reduction in vitro. NYMC X-162 (H3N1, A/Wisconsin/67/2005 HA parent) was
chosen as the first experimental virus because it was one of two of the immunizing viruses
during Immunization Protocol Alpha. But unlike PR8, NYMC X-162 produces lytic plaques
with defined edges that are easily quantified - making it an ideal choice for screening. Data
are shown as a percent reduction relative to total plaque number calculated for virus controls
to account for heterogeneity inherent in viral infection. Anti-HA mAb 2H9 was used as a
conditioned hybridoma supernatant control as it is known to target the HA head and inhibit
viral entry. Of the seven flu mAbs identified in the preliminary Protocol Alpha screen, all
showed some degree of inhibition against NYMC X-162 prior to RDE treatment (Figure
32). However, after treatment with RDE mAb 2G5 conditioned supernatant failed to inhibit
virus at all (Figure 33). Only the 2H9 control and 3 of our candidate antibodies 1G3, 3E9,
and 2A7 retained the ability to inhibit NYMC X-162 following RDE treatment. Next to the
control antibody 2H9, 1G3 containing hybridoma supernatant was the most successful
inhibitor, reducing plaque number by over 50% and 20% at 1:100 and 1:1000 respectively.
(Figure 33).
Due to heterosubtypic binding profile of 1G3 observed in Western blotting, we next
tested 1G3’s ability to inhibit viruses of other subtypes in vitro. In addition to NYMC X-162
(H3N1), three viruses were selected; immunizing virus PR8 (H1N1) as well as an H1N1
pandemic virus (A/California/07/2009) and a wild type H3N2 virus (A/Hong
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Kong/50/2016). These viruses showed reactivity with mAb 1G3 by Western blot and
represent two subtypes of HA currently circulating from each influenza A group. MAb 1G3
containing hybridoma supernatant at a dilution of 1:100 was able to neutralize these viruses
with considerable efficiency, reaching well over 50% neutralization rates for both of the
non-immunizing viruses A/Hong Kong/50/2016 (H3N2) and A/California/07/2009 (H1N1)
(Figure 34). The plaques that developed following infection with A/Hong Kong/50/2016
were observed to be pinpoint sized. We hypothesize that the almost 100% plaque reduction
seen against this virus is as a function of plaques that may not have been observable to the
naked eye.

These data indicate that the binding seen on Western blot has functional

relevance in the context of in vitro replication and infection capacity for these viruses. MAb
1G3 not only binds Group 1 and 2 influenza A viruses, but can also inhibit their ability to
form plaques in cell culture.
Canonically, it was thought that a hallmark of antibodies that bind NA was a
reduction in plaque size. This results from targeting the virus toward the end of the life cycle
and limiting egress of progeny virions. However more recently it has been seen that HA
stem antibodies can also limit plaque size via restricting virus to the endosomal
compartment (133, 137). HA head antibodies function almost exclusively at the attachment
stage and therefore only limit overall plaque number (4, 44). Our antibody candidate 1G3
was first tested for plaque size reduction against NYMC X-162 and demonstrated the ability
to significantly limit plaque size at dilutions of 1:100 and 1:1000 of RDE treated hybridoma
supernatant. 1G3 reduced overall plaque size from an average of 4.3 mm to 1.9 mm and 3.5
mm respectively (Figure 35).
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In addition to NYMC X-162 (H3N1), plaque size was also assessed for
heterosubtypic viruses PR8 (H1N1) and A/California/07/2009 (H1N1pdm) (Figure 36).
Plaque size was not calculated following infection with A/Hong Kong/50/2016 (H3N2), as
infection yielded very small plaques with ill-defined borders. Candidate mAb 1G3 was able
to reduce plaque size following infection with PR8 (H1N1) and A/California/07/2009
(H1N1pdm) as it had for NYMC X-162 (H3N1), suggesting a conserved mechanism of
action across distinct IAV groups.
Elution of a monoclonal antibody during purification is a process that necessitates
reestablishing efficacy to ensure low pH conditions didn’t distort the conformation or
character of an antibody. Results seen with hybridoma supernatant were recapitulated with
purified antibody to ensure data collected was not a result of inhibitors in supernatant that
may survive RDE treatment. Therefore, PRNTs were repeated with multiple concentrations
of purified 1G3 against immunizing virus A/Puerto Rico/8/1934 (PR8, H1N1). Plaque
reduction was maintained and shown to be dose dependent, where the lowest concentration
tested (0.1µg/mL) resulted in a 30% reduction in plaque number (Figure 37). In this model
of infection, 100% plaque reduction is not expected because the initial infection period (30
mins) occurs in the absence of antibody. These results allowed for us to conclude that plaque
number and size reduction upon treatment with 1G3 was as a direct result of antibody
activity and not an inherent property of the hybridoma supernatant.
Finally, we expanded our experimental viral panel to include B/Brisbane/60/2008.
This virus has been the dominant Victoria lineage B virus since its introduction and has been
recommended in vaccine composition by the WHO every year from 2008 till 2018 (24).
Because MAb 1G3 was shown to bind B/Brisbane/60/2008 on Western blot, it was selected
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to be a representative B virus to test via PRNT. We found that RDE treated 1G3 supernatant
was able to significantly reduce plaque number by roughly 50% at a dilution of 1:1000
(Figure 38), demonstrating that 1G3 indeed has functional activity against this B virus. Like
wild type H3 viruses, B plaques have pinpoint morphology with individual diameters that
cannot be measured. Representative images of plaque morphology in virus controls as well
as in the presence of candidate mAb 1G3 can be seen in Figure 39.
Taken together, these PRNT data show that binding on Western blot is indeed
correlated with in vitro neutralization activity of mAb 1G3 against H1, H1pdm, and H3
viruses as well as a wild type B Victoria virus. We can therefore categorize candidate mAb
1G3 as not only broadly binding, but broadly neutralizing. To date, only one other antibody
with activity against influenza A and B, CR9114, has been published (32).
As a qualitative complement to the PRNT data, we next looked at infection in the
presence and absence of mAb 1G3 on the cellular level via indirect fluorescent (IFA)
staining. MDCK cells were seeded into chamber slides and allowed to reach 80-90%
confluency. Cells were then infected with immunizing virus A/Puerto Rico/8/1934 (H1N1)
at a multiplicity of infection (MOI) equal to one. Following 30 mins for viral absorption,
viral inoculum was removed and replaced with cellular growth media, cellular growth media
supplemented with 10 µg/mL purified mAb 1G3, or a commercial isotype control (Figure
40). Unlike a PRNT where an agar overlay is applied to contain virus to plaques, liquid
media was used to allow virus to move into solution and infect the monolayer in a manner
more representative of a natural infection. 24 hours post infection cells were fixed and
stained via IFA. The primary antibody used was 1B3, a PR8 specific anti-HA head mAb
developed in our lab by Dr Yu He. The secondary antibody was an anti-mouse heavy chain
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conjugated with Alexa Fluor 488, allowing infected cells positive for the presence of PR8
HA to be visualized with green fluorescence. We observed that the quality of the cellular
monolayer was greatly improved with the application of neutralizing 1G3 noted as almost no
areas of cell death were seen. Instead the DAPI stained monolayer looked indistinguishable
from the uninfected control. Additionally, positive HA staining was restricted to very few
isolated cells as opposed to the outward spreading in large patches observed in both the virus
and isotype controls (Figure 40). The number of HA positive cells in 1G3 treated chambers
was significantly fewer, while no difference was detected qualitatively or quantitatively
between virus and isotype control cells (Figure 41).
These qualitative data provide further support that mAb 1G3 can not only bind but
also neutralize virus during active in vitro infection. Because these data were obtained with
purified mAb 1G3, we can also conclude that inhibition of viral replication is as a direct
result of antibody 1G3 and not any other components of the hybridoma supernatant.
We have thus far established that candidate mAb 1G3 has functional neutralization
activity in vitro against H1, H1pdm, and H3 viruses as well as influenza B using a PRNT
model. We also have shown using liquid media and fluorescent staining that purified 1G3
significantly alters infection dynamics. We next investigated the ability of purified 1G3 to
inhibit viral replication and growth in ovo against both immunizing viruses, A/Puerto
Rico/8/1934 (PR8, H1N1) and NYMC X-162 (H3N1, A/Wisconsin/67/2005 HA parent) as
well as a representative influenza B virus (BX-31B). The natural reservoir of IAV is aquatic
birds, this combined with the use of chicken eggs in vaccine manufacturing makes the
efficacy of influenza antibodies in infected eggs an important parameter for evaluation (94).
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Influenza A or B viruses at a dilution of 10-8 and purified mAb 1G3 at two
concentrations were co-incubated at 37°C for 30 mins prior to infection. All virus stocks
were diluted in PBS with calcium and gentamicin to maintain virion stability and prevent
bacterial contamination. 11 day Specific Pathogen Free (SPF) embryonated chicken eggs
were first candled to ensure embryonic viability. Eggs were then “windowed” to allow for
ease of allantoic fluid collection without compromising the relative sterility of the egg.
Windowing is done by cutting a 1 cm2 hole in the shell of the egg below in the air sac and
opposite to the embryo in aseptic conditions. Allantoic fluid is collected and the window
covered with UV sterilized parafilm sealed to the intact shell with heated paraffin wax.
Harvested fluid is then assayed for viral content by HA titer and streaked unto Sheep Red
Blood Cell plates to check for any possible confounding bacterial contamination. Fluid was
collected every 12 hours for 72 hours for influenza A viruses and 96 hours for influenza B
starting at time 0, immediately prior to infection. Titers for each experimental run were done
simultaneously in duplicate following final fluid collection to limit variance due to
individual lots of chicken red blood cells. Pre-incubation of virus and antibody at 37°C
allows an antibody to bind any available epitopes prior to inoculation of the egg. It was
observed by Dr Yu He that antibodies that target the HA (head or stem) applied in high
concentrations can prevent infection due to targeting virus at the beginning of the life cycle,
similarly to what is seen in PRNTs. In cells, antibodies that target NA may allow for viral
entry but inhibit egress and are typically associated with a delayed onset of titer as opposed
to total inhibition.
Antibody candidate 1G3 was tested at two concentrations, 1 and 5 µg/mL. At both
concentrations tested, 1G3 prevented rapid PR8 (H1N1) expansion at 36 hours and delayed
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onset of positive viral titer by at least 12 hours. 1G3 at a concentration of 5 µg/mL was able
to suppress viral growth for almost the entirety of the experimental duration (Figure 42).
1G3 was also tested against NYMC X-162 (H3N2) and again delayed the positive onset of
viral titer by at least 12 hours and prevented the virus from reaching its uninhibited max at
72 hours post infection. Unlike what was seen with PR8 infection, 1G3 was not able to
contain NYMC X-162 expansion completely at the higher concentration tested (Figure 43).
Encouraged by the in vitro results, we also tested BX-31B (Victoria). BX-31B is a
high yield reassortant virus prepared by Dr Shiroh Onodera from B/Lee/40 with the HA and
NA components from B/Brisbane/60/2008. Unlike influenza A viruses, influenza B is
slower growing in eggs therefore the infection was allowed to continue for 96 hours total.
Similarly to what was seen with PR8 infection, 5 µg/mL purified 1G3 inhibited infection
totally for the duration of the experiment. Where the uninhibited virus showed considerable
expansion 48 hours post infection, virus pre-incubated with 1 µg/mL 1G3 showed no
positive titer for another 12 hours (Figure 44).
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Figure 33: Percent plaque reduction relative to NYMC X-162 (H3N1, A/Wisconsin/67/2005
HA parent) uninhibited controls of seven hybridoma supernatants prior to treatment with
receptor destroying enzyme. 2H9, a characterized anti-HA head mAb, was used as a
hybridoma supernatant control. Data are shown with supernatants at a final dilution factor
of 1:10 or 1:100. N ≥ 6 wells/condition, shown ± standard deviation, Student’s T Test to
viral control: * = p<0.05, ** = p<0.01, *** = p<0.001
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Figure 34: Percent plaque reduction relative to NYMC X-162 (H3N1, A/Wisconsin/67/2005
HA parent) uninhibited controls of seven receptor destroying enzyme treated hybridoma
supernatants. 2H9, a known anti-HA head mAb, was used as a hybridoma supernatant
control. Data are shown with supernatants at a final dilution factor of 1:100 or 1:1000.
1G9, 1D8, and 2E9 showed no inhibition activity at 1:1000. 2G5 showed no in vitro
inhibition at either dilution. N ≥ 6 wells/condition, shown ± standard deviation, Student’s T
Test to viral control: * = p<0.05, ** = p<0.01, *** = p<0.001
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Figure 35: A/Puerto Rico/8/1934 (PR8, H1N1), A/California/07/2009 (H1N1pdm), A/Hong
Kong/50/2016 (H3N2) and NYMC X-162 (H3N1, A/Wisconsin/67/2005 HA parent) were
used at a concentration of ~40 PFUs/ well. Overlay contained growth media in oxoid agar
or growth media in oxoid agar supplemented with receptor destroying enzyme treated 1G3
hybridoma supernatant at a final dilution of 1:100. N ≥ 6 wells/condition, shown ±
standard deviation, Student’s T Test to respective viral control: * = p<0.05, *** = p<0.001

95

Figure 36: Plaque size reduction mediated by mAb 1G3 vs NYMC X-162 (H3N1,
A/Wisconsin/67/2005 HA parent) at a dilution of 1:1000 and 1:100. N ≥ 6 wells/ condition;
bars show average plaque size ± standard deviation. Student’s T Test: * =p < 0.05, ****
p= <0.0001
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Figure 37: Average plaque size following infection with A/Puerto Rico/8/1934 (PR8,
H1N1), A/California/07/2009 (H1N1pdm), and NYMC X-162 (H3N1, A/Wisconsin/67/2005
HA parent) at a concentration of ~40 PFUs/ well. Overlay contained growth media agar or
growth media agar supplemented with 1G3 containing hybridoma supernatant at a dilution
of 1:100. Plaques were visualized with crystal violet and diameter measured in mm. N ≥ 6
wells/condition, shown ± standard deviation, Student’s T Test: * = p<0.05, ** = p<0.01
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Figure 38: Plaque Reduction and Neutralization Test completed with purified mAb 1G3.
A/Puerto Rico/8/1934 (PR8, H1N1) was applied to 6 well plates at a concentration of ~40
PFUs/ well. Overlay contained control growth media agar or growth media agar
supplemented with purified 1G3 at concentrations shown. N ≥ 6 wells/condition, shown ±
standard deviation, Student’s T Test: * = p<0.05, *** = p<0.001
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Figure 39: Average plaque number following infection with B/Brisbane/60/2008 (Victoria).
Overlay contained growth media agar or growth media agar supplemented with 1G3
containing hybridoma supernatant at a dilution of 1:1000 or 1:100. N ≥ 6 wells/condition,
shown ± standard deviation, Student’s T Test: * = p<0.05, ** = p<0.01
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Figure 40: Representative images of plaque morphology following infection with (from left
to right) A/Puerto Rico/8/1934 (H1N1), NYMC X-162 (H3N1), A/California/07/2009
(H1N1pdm), A/Hong Kong/50/2016 (H3N2), and B/Brisbane/60/2008 (Victoria). Below are
representative images of plaques formed in the presence of candidate mAb 1G3 showing
plaque number and average plaque size reduction.
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Figure 41: Indirect fluorescent staining of A/Puerto Rico/8/1934 (PR8, H1N1) HA in
infected MDCK cells. Primary antibody for stained was 1B3, an PR8 specific anti-HA mAb.
An AlexaFluor488 conjugated secondary was used to visualize infected cells positive for
PR8 HA. Cellular nuclei were stained with DAPI (blue). Images at 20X.
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Figure 42: Following indirect fluorescent staining of MDCK cells, AlexaFluor488 HA+
cells were counted following A/Puerto Rico/8/1934 infection. No significant difference was
observed between virus and isotype controls. N ≥ 3 wells/condition, shown ± standard
deviation, Student’s T Test: ** = p<0.01
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Figure 43: A/Puerto Rico/8/1934 (PR8, H1N1) viral growth represented by the Log of HA
titer. Titer was measured every 12 hours for 72 hours following injection at time point 0 of
PR8 diluted to 10-8 in PBS and gentamicin. 1G3 was pre-incubated with virus at 37°C at
concentrations of 1 or 5 µg/mL. N ≥ 6 eggs/condition, shown ± standard deviation,
Student’s T Test to viral control for each time point: * = p<0.05, *** = p<0.001
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Figure 44: NYMC X-163(H3N1) viral growth represented by the Log of HA titer. Measured
every 12 hours for 72 hours following injection at time point 0 of X-162 diluted to 10-8 in
PBS and gentamicin. 1G3 was pre-incubated with virus at 37°C at concentrations of 1 or 5
µg/mL. N ≥ 6 eggs/condition, shown ± standard deviation, Student's T Test to viral control
for each time point: * = p<0.05, ** = p<0.01
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Figure 45: BX-31B (Victoria) viral growth represented by the Log of HA titer. Measured
every 12 hours for 96 hours following injection at time point 0 of BX-31B diluted to 10-8 in
PBS and gentamicin. 1G3 was pre-incubated with virus at 37°C at concentrations of 1 or 5
µg/mL. N ≥ 6 eggs/condition, shown ± standard deviation, Student's T Test to viral control
for each time point: * = p<0.05, ** = p<0.01, *** = p<0.001
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CONCLUSIONS
Through the immunization of mice with varied influenza hemagglutinin (HA)
proteins, we have generated a novel murine monoclonal antibody 1G3 (IgG1). MAb 1G3
can bind viruses from group 1 and group 2 of influenza A as well both major lineages of
influenza B, Yamagata and Victoria. Using plaque assays, fluorescent staining, and time
course studies, we have shown that mAb 1G3 can also neutralize heterosubtypic viruses to
successfully inhibit infection in vitro and in ovo.
1G3 binds a conformational epitope, making traditional linear mapping difficult.
However, using a peptide array paired with 3D modeling we propose that 1G3 binds the HA
stem near the fusion peptide and across the C terminus of HA1 and the N terminus of HA2.
Although distinct, this putative epitope appears to share many features with the published
epitopes of known broadly neutralizing influenza antibodies. Through sequence alignment
we have also shown that critical residues therein show a high degree of conservation
between different influenza A and B viruses, reflecting strong conservation of the stem
domain.
Influenza’s ability to both drift and shift away from immune recognition makes
vaccination and treatment challenging (24). Antibodies to influenza have been studied in
human and animal sera since the 1970’s (93). Following the advent of hybridoma
technology and various recombinant techniques, hundreds of labs around the world have
attempted to find and target common epitopes. To date, dozens of antibodies have been
identified, published, and patented, that can bind across strains and subtypes. However only
one antibody, CR9114, can protect mice in vivo from lethal challenge with both influenza A
and B (32). Our mAb 1G3 is the first to show activity against A and B viruses in vitro.
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Therefore, mAb 1G3 joins an exclusive class of broadly neutralizing influenza
antibodies. Because of this extremely rare reactivity profile, we believe that 1G3 has the
potential to work in concert with other advances in the field to improve upon currently
available therapies and/or support a universal vaccine.
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DISCUSSION
Influenza epidemics are a major public health concern. Worldwide it is estimated
that annual seasonal infection results in at least 3 million cases of severe illness (requiring
hospitalization) and as many as 650,000 deaths (131). At the height of the 2017-2018 flu
season, 11% of all deaths in the United States were attributed to influenza and influenza like
illness in addition to 185 reported pediatric deaths. This was the highest number of pediatric
deaths since infant and child mortality from influenza became a reportable illness. 80-90%
of these deceased patients were unvaccinated (17). Influenza pandemics can result from the
introduction of novel flu proteins into an immunologically naive human population. The
most recent “Swine Flu” pandemic in 2009 infected an estimated 65 million people and
caused a significant amount of morbidity in typically lower risk groups, especially young
adults (109). The 1918 “Spanish Flu” was even more devastating, estimated to have killed
roughly 5% of the global population at the time.
Unfortunately, treatment for influenza infection is significantly limited. Until very
recently only two classes of drugs were approved for the management of flu, M2 ion
channel inhibitors and NA inhibitors (NAIs) (77). M2 ion channel inhibitors were developed
first and function to prevent the acidification of the viral core and subsequent uncoating
(100, 124). Although initially effective, over time their use has selected for resistant strains
that maintain pathogenicity - which now predominate the infection landscape (124). The
CDC recommends against their use as efficacy is at an all-time low (17). NAIs like
Tamiflu™ and Relenza™ interfere with the activity of the viral neuraminidase, allowing
virus to gain entry into host cells but preventing progeny virion release. Several large-scale
retrospective studies have demonstrated that NAIs are effective as prophylaxis for those
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populations most at risk of complications from influenza infection. However, as treatment
NAIs are limited and have been met with mixed success (73, 87). Replication in the
respiratory tract generally peaks 24-48 hours post infection. Therefore NAIs have to be
prescribed very early in disease course, representing a significant hurdle to their continued
use and success (77). NAIs have also been used as a therapeutic modality for patients who
are already hospitalized with severe illness, although this is considered off label and most
studies show no advantage of the use the NAIs over traditional supportive therapies (39, 59).
Resistance mutations are rare but have been recorded in some seasonal H1N1 viruses (73).
Regular vaccination remains both the most operative and cost-effective way to
control influenza. Current seasonal influenza vaccines are effective against infection but are
not without shortcomings. Due to constant antigenic drift and occasional shift of circulating
viruses, vaccines need to be reformulated and redistributed to the general public each year.
Despite significant effort, mismatches do occur that may leave even vaccinated individuals
vulnerable to illness. Trivalent and tetravalent vaccines are only partially effective in the
most susceptible target populations, including the elderly and immunocompromised. (24,
121, 141). Crucially, seasonal vaccines provide no protection against novel strains,
significantly limiting pandemic preparedness (82).
Perhaps the most significant limitation in our current vaccination strategy is that it
generally induces a narrow and strain specific response (7, 48). Antibodies developed
following vaccination are most often targeted to the highly variable loops on the globular
HA head that surround the receptor binding site (127). HA head binding antibodies are very
adept at neutralization because they prevent the virus from binding to the sialic acid
receptors necessary for the virus to gain entry into a host cell. Some HA head antibodies can
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also interfere with the function of the viral NA through steric hindrance, preventing viral
egress as well as endocytosis (80, 130). However, in addition to being largely strain specific
these antibodies readily select for escape mutations and lose efficacy quickly against drifted
strains (11).
New prevention and treatment modalities for influenza are needed. Recently several
human antibodies with wider neutralizing activity have been isolated using single B cell
identification techniques, phage display libraries, and hybridoma cell lines (123). These
broadly neutralizing monoclonal antibodies (bnmAbs) have been characterized following
vaccination with heterosubtypic HA, but are comparatively rare following natural infection
(133).
Broadly neutralizing influenza antibodies are divided into three types based on the
breadth of viruses they have been demonstrated to inhibit. Type 1 are effective against
several group 1 influenza A viruses, Type 2 against several group 2, and Type 3 which are
effective many HA subtypes belonging to both groups 1 and 2 (137). There are also a
handful of broadly neutralizing antibodies which target influenza B, these are characterized
as having activity against a subset of viruses of both the major B lineages (32). Many of
these antibodies have been shown to be of therapeutic or prophylactic benefit in animal
models and are summarized in Figure 45.
Therapeutic Antibodies
There is a significant existing framework for the use of targeted monoclonal
antibodies in the treatment of human diseases, including autoimmune disorders,
cardiovascular pathologies, cancer, and some bacterial infections. The earliest iterations of
antibody therapy were murine antibodies developed using hybridoma cell lines and were
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largely disappointing. Unfortunately mouse derived molecules failed to interact as predicted
in a human immunological context and were not only ineffective, but dangerous as they
were recognized as foreign by the patient resulting in inflammation and their subsequent
elimination (19). The era of antibody engineering quickly followed with the advent of the
first chimeric and then humanized mAbs. Chimeric antibodies are generated by fusing the
murine variable domain with a human constant domain and are roughly 70% human origin.
In addition to being less immunogenic, chimeric antibodies can bind their intended target
while still interacting with the patient’s own Fc receptors (67). Humanized antibodies were
developed shortly thereafter by replacing the antigen binding hypervariable loops of a
human antibody with the targeted murine loops – a process known as “complementaritydetermining region grafting”. Humanized antibodies are nearly 90% human but cost more to
produce as often mutagenesis via a phage library is needed post hoc to restore high affinity
binding. Almost all of the mAbs approved in the United States currently are either chimeric
or humanized (19).
Despite the over 60 FDA approved mAbs to date there is only a single antiviral
antibody widely available; Palivizumab for Respiratory Syncytial Virus (RSV) prophylaxis
in high risk infants (123). The reason for the limited development of virally targeted
antibodies is a combination of factors, including high production cost, difficulties related to
administration, and the belief that antibodies are most effective prior to exposure - which for
many viruses is made redundant by vaccination. However there is a growing appreciation of
the potential of many novel antiviral mAbs, including the now infamous Ebola virus mAb
Porgaviximab, also known as Zmapp (95). More antiviral antibodies will continue to come
to market as the increased potency of superior antibodies reduces the cost of production and
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makes patient compliance more feasible and less expensive by also reducing the number of
treatments needed. This coupled with a new generation of technologies for antibody
generation, including humanized animals, single B cell cloning, and combinatorial display
libraries, is the cause of much cautious optimism for combatting notoriously difficult viruses
like HIV as well as emerging threats like MERS coronavirus (123).
Antibodies can act against viruses in several defined ways but are generally divided
into two categories: those which act on viral particles and those which target infected cells.
The best measure of activity on free virus is known as neutralization; or the ability of an
antibody to prevent viral entry. Neutralization is measured in vitro and has been shown to be
a strong correlate of in vivo protection for a wide range of viruses (74). Neutralization for
influenza viruses is measured as blockade of either HA or NA through HI, NI, or PRNT
assays (28). However for some viruses, and for influenza viruses in particular, activity
against infected cells in the intact host immunological context appears to be critical for
antibody efficacy - as in vitro neutralization titers often do not predict in vivo protection (26,
51, 105, 113). These antibodies interact with the host Fc receptors and may incite a number
of complex downstream processes including antibody-dependent cytotoxicity (ADCC),
complement-dependent cytotoxicity (CDC), and antibody-dependent cellular phagocytosis
(ADCP) (36, 106, 123, 127). Meaning that despite commonly held wisdom, the constant
regions of these antibodies are as critical for in vivo protection, if not more so, than the
antigen binding variable region.
There is growing evidence for the role of ADCC in the influenza immune response
as mediated by some HA antibodies. ADCC is a mechanism by which Fc receptor bearing
natural killer (NK) cells recognize antibody bound cells and release cytotoxic granules into
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an immunological synapse formed between the NK cell FcγRIIIa and its target. These
granules generally contain a combination of perforin and granzyme B and their release
results in the apoptosis of the infected cell (19, 76). It has been demonstrated that stalk mAb
efficacy is dependent on the presence of functioning Fcγ receptors, as transgenic mice
lacking Fcγ receptors on murine NK cells are not protected from lethal challenge by anti-HA
stalk mAbs (28, 57). Interestingly, this same requirement has not been seen for strain
specific HA head antibodies, which are effective regardless of NK cell presence (29).
The basis of this observation lies in a difference of mechanism for head and stalk
antibody function. While head antibodies prevent virus binding similarly in vitro and in vivo,
most stalk antibodies show a very different mechanistic profile in cells and in animals. AntiHA stalk antibodies may primarily inhibit endocytic membrane fusion in vitro, but in the
complete immunological context of an animal these same antibodies function primarily
through the activation of ADCC (29, 57, 122). These data may provide a framework of
understanding why our mAb 1G3 was more effective at lower concentrations in ovo than in
PRNT cellular assays against the same A/Puerto Rico/8/1934 virus. Chicken embryos
produce T and B cells by day 11 and 12 of development and do have an avian NK cell
homologue known as TCRO (58, 83). Therefore, our in ovo studies may be more
representative of the true neutralizing potential of 1G3 which like other stalk mAbs may
interact with NK cells to target and destroy virally infected cells. These observations also
support the data obtained with mAb CR9114 where in vitro neutralization was absent
against those viruses whereas CR9114 did protect against in mice with functioning NK cells
(32). However, it is important to note that were CR9114 failed to inhibit influenza B viruses
in cells, our mAb 1G3 was successful. Therefore 1G3 activity is not dependent on ADCC
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alone.
Despite their many advantages, monoclonal antibodies are subject to more than a few
major limitations and therapeutic considerations. First there are several practical issues,
namely cost. Because monoclonal antibodies are complex molecules that require extensive
eukaryotic machinery in order to be properly synthesized, production relies on very large
cultures of mammalian cells followed by many steps of purification in order to be approved
for infusion or injection into a human patient (19, 34, 136). High cost is also directly
proportional to the high concentration of mAbs needed for human efficacy. For example,
Natalizumab, also known as Tysabri, is a humanized IgG4 developed to treat Multiple
Sclerosis. Natalizumab is given to patients as 300 mg IV infusion every 28 days for an
indefinite period of time, often many years, requiring at least 4 grams of antibody per patient
per year (8). This scheme is common among current therapeutic models for chronic disease,
however dosing for acute conditions is less clear. As reference, Palivizumab is given
prophylactically at 15 mg/kg of body weight every 28 days during the RSV season until the
child reaches 2 years old or is no longer considered at risk (110).
Interestingly, the high effective serum concentration needed of human antibodies
might be because of Fc receptor dependent mechanisms of action. Some therapeutic
antibodies saturate ADCC function in vitro at concentrations as low as 10 ng/µL but require
effective serum concentrations between 10 and 100 µg/µL (19). Its hypothesized that this
may be as a result of competition from a patient’s own circulating IgG for available
FcγRIIIa receptors, as IgG1 has a very high mean serum level in adults (55). It has also been
demonstrated that affinity between a therapeutic antibody and a patients Fc receptor may be
a predictive measure of efficacy. Unfortunately, about 80% of the world’s population

114

expresses FcγRIII-F158, a low affinity variant of the receptor which may also contribute to
high antibody effective concentrations (127). Another consideration is that like natural
human IgG1, therapeutic IgG1 can interact with both classes of Fcγ receptors. ADCC occurs
through activating receptors, but inhibitory receptor FcγRIIb is expressed on B-cells,
macrophages, and dendritic cells. Where FcγRIII possesses a tyrosine activation motif,
FcγRIIb does not and binding to this receptor sequesters and decreases the overall efficacy
of exogenous mAbs (19).
Influenza Monoclonal Antibodies
There are currently eight anti-influenza antibodies listened as in clinical trials in the
US. Of these, seven target HA while one targets the extracellular domain of the M2 ion
channel. Most have been developed within the last 10 years using single B cell isolation
from vaccinated patient volunteers. These are summarized in Figure 46.
The HA protein is encoded by RNA segment 4 and is moved across the host rough
endoplasmic reticulum during translation. HA is synthesized as a monomer, HA0, which is
composed of 549 amino acids and undergoes significant N linked glycosylation. HA0 is
assembled into trimers at the virion surface and then must be cleaved into its active subunits
HA1 (327 amino acids) and HA2 (222 amino acids) in order to be active (109). HA0
cleavage is a major determinant of tissue tropism and occurs via a trypsin-like serine
protease at a cleavage site encoded by a single arginine residue (R329) in most influenza A
viruses (117). HPAI viruses have well characterized mutations at this cleavage site that
result in the insertion of several basic residues near the requisite arginine, resulting in the
ability to be cleaved intracellularly by more ubiquitous enzymes like furin (112). Following
cleavage, the hydrophobic fusion peptide on the N terminal domain of HA2 relocates to the
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trimer interior forming the fusion peptide pocket and becomes fusogenic (25, 66). However,
HA1 and HA2 stay associated via disulphide bonds throughout viral entry. HA then
undergoes significant conformational change in response to the acidification of the
endocytic vesicle, including the disassociation of the HA1 domain from the HA2 fusion
domain (42). This results in the extrusion of the fusion peptide from the interior pocket
while the C terminal domain of HA2 stays anchored in the viral membrane. This structure
collapses by “zipping up” and drives the fusion of the endosomal and virion membranes,
necessary for the release of viral contents into the cytoplasm (25).
HA can be divided into two structural domains, the globular head and the stem. The
globular head contains the receptor binding domain, as well as part of a vestigial esterase,
while the stem contains the fusion peptide and the remaining esterase residues. The receptor
binding domain is located at the top of the globular head and is composed of the 130 loop,
190 helix, and 220 loop; all encoded by HA1 along with the proximal antigenic sites (69,
109). In contrast, the fusion domain includes residues from both HA1 and HA2. The fusion
domain sits in the stem is encoded by the N and C terminal domains of HA1 (amino acids
11-64, 276-329) as well as the N terminal domain of HA2 (amino acids 1-160) (132).
Traditional HA head targeted antibodies subvert the propagation of infection by
preventing the HA receptor binding pocket from appropriately interacting with its sialic acid
ligand and are associated with positive experimental hemagglutinin inhibition (97). However
broadly neutralizing HA stem antibodies have been shown to be effective against influenza
in vitro and in vivo by several mechanisms, irrespective of sialic acid binding (Figure 47).
Of these, inhibition of fusion between the virus and endosome has been observed in relation
to all broadly neutralizing stem MAbs (11). It was previously hypothesized that stem mAbs
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are internalized together with virus and reach the late endosome where binding to their
epitope prevents the fusion peptide from responding to low pH (71). Indirect evidence for
this reasoning has been the lack of detectable HAI activity, inhibition of conformational
changes in recombinant HA, and the prevention of syncytia formation in HA expressing
cells (35, 85, 111).

Friessen et al have demonstrated using single particle tracking

technology that mAb CR8020, a stem antibody which neutralizes multiple Group 2 flus, is
in fact internalized by live cells during infection and are capable of reaching the late
endosomes (11). CR8020 was developed through human B cell isolation by Crucell and is
currently in phase II clinical trials supported by Johnson and Johnson (32, 123)
Due to the close structural relationship between the fusion peptide and cleavage site
that separates HA1 and HA2, epitopes that prevent endosomal fusion may also prevent
proteolytic activation of HA exterior to the cell and prior to receptor mediated endocytosis.
While fusion inhibition is widely reported as the dominant mechanism of virus
neutralization, this second means of inhibiting virus has been shown to add to the strength of
some broadly neutralizing mAbs (68, 109, 112). Our own data for mAb 1G3 suggests that
both of these mechanisms may be involved. Linear epitope mapping and 3D protein
visualization show that the most likely epitope is near the fusion peptide, at the C terminus
of HA1 and N terminus of HA2. Additionally, for Group 2 viruses trypsin treatment
disrupted 1G3 binding; suggesting that the cleavage site could plays an integral role in
recognition of H3 viruses.
The third mechanism by which stem antibodies may inhibit cellular viral infection is
through the interference of viral egress. It was previously accepted that only NA targeted
antibodies prevented the release of progeny virions, as the primary function of NA is to
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cleave sialic acid at the surface and prevent HA cross linking (47, 77, 129). Recent studies
using scanning electron microscopy have shown that some HA targeted antibodies may also
inhibit virion escape, although there is some debate about the exact mechanism (28, 57). It
appears that antibodies with specific VH regions may participate directly in cross-linking
bound virions at the surface of the cell while others may function indirectly through steric
hindrance of NA activity (68, 130). We found that mAb 1G3 does in fact limit virion egress,
as evidenced by significant plaque size reduction against both H1 and H3 influenza A
viruses. Furthermore, we believe this is through indirect inhibition of the viral NA, as 1G3
mediated NA inhibition is ablated by treating virus with a strong detergent.
The only antibody described to date that can bind and neutralize both influenza A
Groups 1 and 2 as well as influenza B viruses is CR9114 (32). CR9114 was generated using
single B cell isolation from human volunteers who received regular season vaccination and
constructing combinatorial phage display libraries. CR9114 has been shown to be capable of
neutralizing H1, H2, H3, H4, H5, H6, H7, H8, H9, H10, H12 viruses in vitro. CR9114
initially showed no activity against any influenza B viruses. However, they found CR9114
fully protected mice from lethal challenge with B/Florida/4/2006 and B/Malaysia/2506/2004
when given prophylactically 24 hours post infection at a concentration of 15 mg/kg. Lower
concentrations were needed for 100% survival against influenza A viruses, as low as 1.7
mg/kg for both A/Puerto Rico/8/1934 (H1N1) and A/Hong Kong/1/1968 (H3N2) (35).
Recently CR9114 was also evaluated prophylactically against a panel of H2 viruses, which
although not currently circulating in humans remains a threat due to a persistent animal
reservoir. As with influenza B, CR9114 showed weak activity in cells but was protective
against a lethal challenge with both A/Ann Arbor/6/1960 and A/swine/MO/4296424/2006 at
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a concentration of 5 mg/kg (113). These effects were dependent on the presence of Fcγ
receptors and again demonstrate the importance of ADCC within in vivo studies for
analyzing stalk mAbs which may not neutralize efficiently in cells. While 1G3 shares some
epitopic features with CR9114, it has been shown to be broadly neutralizing in vitro,
therefore the role of ADCC in 1G3 efficacy remains to be seen.
Future Directions
Monoclonal antibody 1G3 represents a new member in the broadly neutralizing
group. While its epitope is similar, and indeed overlaps with that of other known HA stem
antibodies, its in vitro neutralization profile is unrivaled. Further work will focus on
establishing the 1G3 epitope with a higher resolution, exploring the possible mechanism or
mechanisms of action with respect to different lineages of influenza, as well as establishing
in vivo relevance.
The gold standard for establishing antibody epitopes is X-ray crystallography. Here
the target protein and antibody are allowed to bind and then purified in high concentrations
in a crystalline form. When a single X-ray beam is applied, the resulting pattern of
diffraction can be used to obtain data on “crystal packing” which can be translated into
electron density and therefore atoms and amino acids (38, 108). This method has yielded an
incredible amount of data, including the discovery of the structure of DNA by Rosalind
Franklin for which Watson, Crick, and Wilkins received the Nobel prize in 1962. Images of
experimental antibody bound to purified HA obtained using X-ray crystallography allow the
researcher to identify single amino acids that contribute to affinity. Unfortunately, as a
technique crystallography is expensive and exceedingly difficult. Crystalizing a protein can
take upwards of one year which is compounded in our use by crystalizing a protein-antibody
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interaction. Crystals need to be of the highest purity and in large concentrations to have
regular repeating unit cells that can be easily interpreted. Proteins are generally crystalized
in solution, although discerning the best conditions for nucleating high quality crystals is
almost always a process of trial and error (1). While X-ray crystallography is accepted as
the ideal, we may instead consider site directed mutagenesis to complement the data
obtained from our linear array. When comparing the mapping data across group 1, group 2,
and influenza B viruses we found some highly conserved amino acids within the predicted
1G3 footprint on both HA1 and HA2. We could systematically mutate these single amino
acids and then retest 1G3’s ability to bind HA antigen either via ELISA or Western blot and
thereby identify those sites which may contribute the most to affinity. Although site directed
mutagenesis is also time intensive, it is significantly less costly than X-ray crystallography
and would improve our resolution from 15 amino acid long stretches, instead highlighting a
few critical residues.
One important observation from our data is that although 1G3 is effective in vitro
and in ovo against both H1 and H3 viruses, the banding pattern on Western blot is different;
especially with respect to trypsin treatment. While performing an additional peptide map
with any one of the H3 viruses we assayed might yield a radically different epitope, it's more
likely that the difference between H1 and H3 binding is based in conformational
dissimilarities that are not apparent in a linear array. Instead there are other some
experiments which may be able to discern differences in mechanism of 1G3 inhibition
between H1 and H3 viruses. We suspect that 1G3 inhibits membrane fusion as that has been
implicated with every HA stem antibody in the literature. However, testing the relative
efficacy of 1G3 against H1 and H3 mediated fusion would provide some operational insight.
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There are two widely accepted approaches to measuring fusion inhibition by stem
antibodies. The first is to transiently express the HA of a virus type of interest, here at least
one H1 and one H3 virus, on the surface of HeLa cells or another similarly permissive cell
line. At a pH of roughly 5.0 the HA expressed on these cells will allow for the formation of
syncytia that are easily seen and scored with a light microscope. We would predict that
syncytia formation by H1 or H3 protein would be inhibited by a sufficient concentration of
mAb 1G3, although we would likely observe that concentrations would differ between HAs.
However, mAb 1G3 did not bind recombinant HA on Western blot and is acutely
sensitive to HA conformation, therefore transient surface expression from a plasmid may not
best reflect the activity of 1G3. Another experiment which may be better suited to 1G3’s
unique character involves directly observing membrane fusion through a single particle
fusion assay developed by Crucell, the same group who developed CR9114 and CR8020.
The enveloped membrane of virus is first labeled with fluorescent lipophilic dye in a
concentration sufficient to result in self-quenching. Following pre-incubation with either a
control or the stem antibody of interest, the virus-antibody complexes are bound to sialic
acid residue embedded in a target membrane and imaged. When the pH is lowered from 7.4
to 5, fusion is measured as a rapid increase in fluorescence signal due to de-quenching
through diffusion. Live imaging of this event would provide direct evidence of inhibition of
membrane fusion by 1G3 on intact virions with biologically relevant HA.
Another possible mechanism of action for 1G3 is the prevention of proteolytic
cleavage of HA prior to viral internalization. We saw that following overnight trypsin
treatment 1G3 could no longer bind purified H3 virus on Western blot, heavily implicating
the protease recognition site in antibody binding. We would also like to incubate both H1
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and H3 viruses with 1G3 first, then probe with 1G3 by Western blot following overnight
treatment with trypsin. We suspect that the 1G3 epitope straddles the trypsin recognition site
for both H1 and H3 viruses and therefore only one band would be visible in reducing
conditions as the HA0 monomer would remain intact. However, more important than this
would be to test the additive effect of inhibition of cleavage in vitro. To do this we would
need to generate a batch of each virus of interest with uncleaved HA. As MDCK cells do not
produce any proteases capable of cleaving HA endogenously, this can be accomplished by
harvesting virus after a single round of replication in the absence of exogenous trypsin.
These viruses will be incompetent for infection. We would then test the contribution of
cleavage inhibition by incubating with 1G3 following trypsin treatment of virus or before. If
uncleaved virus is incubated with trypsin and then 1G3, the subsequent infection would
assay neutralization only the remaining inhibition points, membrane fusion or egress.
However, if uncleaved virus and 1G3 are co-incubated together prior to trypsin treatment,
the pursuant infection would reflect neutralization by both blocking HA cleavage and
membrane fusion. We would expect that adding 1G3 before trypsin treatment would result
in the most significant plaque reduction in a PRNT context, as inhibition of cleavage is a
supplemental mechanism of viral inhibition that will have an additive effect on controlling
in vitro infection. We would also expect this effect to be even more pronounced with H3
viruses as is appears from Western blotting that 1G3 binding is disrupted by cleavage.
Most critically, the efficacy of 1G3 needs to be evaluated in vivo. We would first
model our experiments based on those completed with CR9114 by Dreyfus et al. They
evaluated the prophylactic efficacy of their antibody by applying 15, 5, 1.7, 0.6, or 0.2
mg/kg intranasaly 24 hours post challenge with 25 LD50 of virus. They measured the
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animal’s survival and body weight for 15 days and also measured viral titer in the lungs
following sacrifice (32). We would ideally test at minimum one H1, one H3 and one
influenza B virus from each lineage in a similar infection scheme. It would also be of
interest to test 1G3 prophylactically against a HPAI H5 or H7 virus, which would require
the use of a dedicated BSL-3 animal facility in addition to a BSL-3 laboratory for viral
propagation and preparation.
We would also like to test the impact of 1G3 as a possible therapeutic in vivo. Our
PRNT protocol does call for the application of antibody following 30 mins of infection and
those data strongly suggest that 1G3 can dampen an already in-progress infection. Especially
salient would be any effect of 1G3 on highly pathogenic avian viruses post infection, as
these carry a high mortality rate but have been successfully treated with convalescent sera
(3).
Interestingly, there are no data available about the therapeutic value of CR9114.
However, another antibody also developed by Crucell, CR8020, completed Phase 2a human
clinical trials less than 5 years ago. They tested a single 15 mg/kg injection given 2 days
post challenge with an H1N1 virus. Unfortunately, study data are not available. Yet another
Crucell antibody, CR6261, is currently being evaluated with its own Phase 2a trial at a
reported concentration of 50 mg/kg. This discrepancy drives home the importance of in vivo
experimentation and the difficulties of antibody therapies for infectious disease.
While there is a significant amount of work needed to translate monoclonal antibody
1G3 from our data to human relevance, we are optimistic that because of 1G3’s broad
neutralizing profile it is worth pursuing.
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Figure 46: Influenza HA targeted broadly neutralizing monoclonal antibodies. Type 1
antibodies target more than one strain of group 1; type 2 targets more than one strain of
group 2. Type 3 can target influenza A strains of both groups. CR9114 (highlighted in red)
can also target influenza B (32).
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Figure 47: Influenza targeted monoclonal antibodies currently in development in the United
States. Seven of eight target the HA glycoprotein while one, TCN 032, instead targets the
extracellular region of the M2 ion channel.
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Figure 48: Mechanisms of HA antibody inhibition of influenza virus infection. Head
targeted antibodies function primarily at the beginning of the virus life cycle, shown on the
left, preventing viral attachment. Stem antibodies, right, may prevent HA cleavage before
internalization or prevent pH mediated conformational changes in the fusion peptide. Both
head and stem antibodies can prevent the egress of progeny virions either by directly
crosslinking virus or indirectly inhibited NA via steric hindrance. (11)
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APPENDIX

1. Table of Viruses

Virus

Abbreviation

Subtype

Origin

PR8

IAV, H1N1

Egg adapted

IAV, H1N1

Wildtype

A/Moscow/10/1
999

IAV, H3N2

Wildtype

A/Wisconsin/67/
2005

IAV, H3N2

Wildtype

A/South
Dakota/06/2007

IAV, H1N1

Wildtype

A/California/07/
2009

IAV, H1N1pdm

Wildtype

A/Hong
Kong/50/2014

IAV, H3N2

Wildtype

B/Brisbane/60/2
008

IBV, Victoria

Wildtype

B/Massachusetts
/02/2012

IBV, Yamagata

Wildtype

A/Puerto
Rico/8/1934
A/New
Caledonia/20/19
92

Gene
Composition

NYMC X-162

X-162

IAV, H3N1

High Yield
Reassortant

HA:
A/Wisconsin/67/
2005

NYMC X-179A

X-179A

IAV, H1N1pdm

High Yield
Reassortant

HA, PB1:
A/California/07/
2009

NYMC X-187

X-187

IAV, H3N2

High Yield
Reassortant

HA:
A/Victoria/2009
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2. Peptide Map

EQKLISEEDL

1
G
GSGSGSGMKA
NLLVL
GSGSGSGMKA
NLLVL
LCRLKGIAPLQL
GKC
LCRLKGIAPLQL
GKC
LSSVSSFERFEIF
PK
LSSVSSFERFEIF
PK
GKEVLVLWGIH
HPSN
GKEVLVLWGIH
HPSN
LKPGDTIIFEAN
GNL
LKPGDTIIFEAN
GNL
VTIGECPKYVR
SAKL
VTIGECPKYVR
SAKL
AADQKSTQNAI
NGIT
AADQKSTQNAI
NGIT
LVLLENERTLD
FHDS
LVLLENERTLD
FHDS
SEESKLNREKV
DGVK
SEESKLNREKV
DGVK
G

2
EQKLISEEDL
SGSGSGMKANL
LVLL
SGSGSGMKANL
LVLL
CRLKGIAPLQL
GKCN
CRLKGIAPLQL
GKCN
SSVSSFERFEIFP
KE
SSVSSFERFEIFP
KE
KEVLVLWGIHH
PSNS
KEVLVLWGIHH
PSNS
KPGDTIIFEANG
NLI
KPGDTIIFEANG
NLI
TIGECPKYVRS
AKLR
TIGECPKYVRS
AKLR
ADQKSTQNAIN
GITN
ADQKSTQNAIN
GITN
VLLENERTLDF
HDSN
VLLENERTLDF
HDSN
EESKLNREKVD
GVKL
EESKLNREKVD
GVKL
EQKLISEEDL

3
G
GSGSGMKANLL
VLLC
GSGSGMKANLL
VLLC
RLKGIAPLQLG
KCNI
RLKGIAPLQLG
KCNI
SVSSFERFEIFPK
ES
SVSSFERFEIFPK
ES
EVLVLWGIHHP
SNSK
EVLVLWGIHHP
SNSK
PGDTIIFEANGN
LIA
PGDTIIFEANGN
LIA
IGECPKYVRSA
KLRM
IGECPKYVRSA
KLRM
DQKSTQNAING
ITNK
DQKSTQNAING
ITNK
LLENERTLDFH
DSNV
LLENERTLDFH
DSNV
ESKLNREKVDG
VKLE
ESKLNREKVDG
VKLE
G

4
EQKLISEEDL
SGSGMKANLLV
LLCA
SGSGMKANLLV
LLCA
LKGIAPLQLGK
CNIA

5
G
GSGMKANLLV
LLCAL
GSGMKANLLV
LLCAL
KGIAPLQLGKC
NIAG

6
EQKLISEEDL
SGMKANLLVLL
CALA
SGMKANLLVLL
CALA
GIAPLQLGKCNI
AGW

7
G
GMKANLLVLL
CALAA
GMKANLLVLL
CALAA
IAPLQLGKCNIA
GWL

1

EQKLISEEDL
EQKLISEEDL

2

G

3

EQKLISEEDL

4

G

5

EQKLISEEDL

6

G

7

EQKLISEEDL

8

G

9

EQKLISEEDL

10

G

11

EQKLISEEDL

12

G

13

EQKLISEEDL

14

G

15

EQKLISEEDL

16

G

17

EQKLISEEDL

18

G

1
2
3
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4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

1
2
3
4
5
6
7
8
9
10

LKGIAPLQLGK
CNIA
VSSFERFEIFPK
ESS
VSSFERFEIFPK
ESS
VLVLWGIHHPS
NSKE
VLVLWGIHHPS
NSKE
GDTIIFEANGNL
IAP
GDTIIFEANGNL
IAP
GECPKYVRSAK
LRMV
GECPKYVRSAK
LRMV
QKSTQNAINGIT
NKV
QKSTQNAINGIT
NKV
LENERTLDFHD
SNVK
LENERTLDFHD
SNVK
SKLNREKVDGV
KLES
SKLNREKVDGV
KLES
EQKLISEEDL

KGIAPLQLGKC
NIAG
SSFERFEIFPKES
SW
SSFERFEIFPKES
SW
LVLWGIHHPSN
SKEQ
LVLWGIHHPSN
SKEQ
DTIIFEANGNLI
APM
DTIIFEANGNLI
APM
ECPKYVRSAKL
RMVT
ECPKYVRSAKL
RMVT
KSTQNAINGITN
KVN
KSTQNAINGITN
KVN
ENERTLDFHDS
NVKN
ENERTLDFHDS
NVKN
KLNREKVDGV
KLESM
KLNREKVDGV
KLESM
G

GIAPLQLGKCNI
AGW
SFERFEIFPKESS
WP
SFERFEIFPKESS
WP
VLWGIHHPSNS
KEQQ
VLWGIHHPSNS
KEQQ
TIIFEANGNLIAP
MY
TIIFEANGNLIAP
MY
CPKYVRSAKLR
MVTG
CPKYVRSAKLR
MVTG
STQNAINGITNK
VNT
STQNAINGITNK
VNT
NERTLDFHDSN
VKNL
NERTLDFHDSN
VKNL
LNREKVDGVKL
ESMG
LNREKVDGVKL
ESMG
EQKLISEEDL

IAPLQLGKCNIA
GWL
FERFEIFPKESS
WPN
FERFEIFPKESS
WPN
LWGIHHPSNSK
EQQN
LWGIHHPSNSK
EQQN
IIFEANGNLIAP
MYA
IIFEANGNLIAP
MYA
PKYVRSAKLRM
VTGL
PKYVRSAKLRM
VTGL
TQNAINGITNK
VNTV
TQNAINGITNK
VNTV
ERTLDFHDSNV
KNLY
ERTLDFHDSNV
KNLY
NREKVDGVKLE
SMGI
NREKVDGVKLE
SMGI
G

8
EQKLISEEDL
MKANLLVLLC
ALAAA
MKANLLVLLC
ALAAA
APLQLGKCNIA
GWLL
APLQLGKCNIA
GWLL
ERFEIFPKESSW
PNH
ERFEIFPKESSW
PNH
WGIHHPSNSKE
QQNL
WGIHHPSNSKE
QQNL
IFEANGNLIAPM
YAF
IFEANGNLIAPM
YAF

9
G
KANLLVLLCAL
AAAD
KANLLVLLCAL
AAAD
PLQLGKCNIAG
WLLG
PLQLGKCNIAG
WLLG
RFEIFPKESSWP
NHN
RFEIFPKESSWP
NHN
GIHHPSNSKEQ
QNLY
GIHHPSNSKEQ
QNLY
FEANGNLIAPM
YAFA
FEANGNLIAPM
YAFA

10
EQKLISEEDL
ANLLVLLCALA
AADA
ANLLVLLCALA
AADA
LQLGKCNIAGW
LLGN
LQLGKCNIAGW
LLGN
FEIFPKESSWPN
HNT
FEIFPKESSWPN
HNT
IHHPSNSKEQQ
NLYQ
IHHPSNSKEQQ
NLYQ
EANGNLIAPMY
AFAL
EANGNLIAPMY
AFAL

11
G
NLLVLLCALAA
ADAD
NLLVLLCALAA
ADAD
QLGKCNIAGWL
LGNP
QLGKCNIAGWL
LGNP
EIFPKESSWPNH
NTN
EIFPKESSWPNH
NTN
HHPSNSKEQQN
LYQN
HHPSNSKEQQN
LYQN
ANGNLIAPMYA
FALS
ANGNLIAPMYA
FALS
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11
12
13
14
15
16
17
18

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17

KYVRSAKLRM
VTGLR
KYVRSAKLRM
VTGLR
QNAINGITNKV
NTVI
QNAINGITNKV
NTVI
RTLDFHDSNVK
NLYE
RTLDFHDSNVK
NLYE
REKVDGVKLES
MGIY
REKVDGVKLES
MGIY
EQKLISEEDL

YVRSAKLRMV
TGLRN
YVRSAKLRMV
TGLRN
NAINGITNKVN
TVIE
NAINGITNKVN
TVIE
TLDFHDSNVKN
LYEK
TLDFHDSNVKN
LYEK
EKVDGVKLES
MGIYQ
EKVDGVKLES
MGIYQ
G

VRSAKLRMVT
GLRNI
VRSAKLRMVT
GLRNI
AINGITNKVNT
VIEK
AINGITNKVNT
VIEK
LDFHDSNVKNL
YEKV
LDFHDSNVKNL
YEKV
KVDGVKLESM
GIYQI
KVDGVKLESM
GIYQI
EQKLISEEDL

RSAKLRMVTGL
RNIP
RSAKLRMVTGL
RNIP
INGITNKVNTVI
EKM
INGITNKVNTVI
EKM
DFHDSNVKNLY
EKVK
DFHDSNVKNLY
EKVK
VDGVKLESMGI
YQIL
VDGVKLESMGI
YQIL
G

12
EQKLISEEDL
LLVLLCALAAA
DADT
LLVLLCALAAA
DADT
LGKCNIAGWLL
GNPE
LGKCNIAGWLL
GNPE
IFPKESSWPNHN
TNG
IFPKESSWPNHN
TNG
HPSNSKEQQNL
YQNE
HPSNSKEQQNL
YQNE
NGNLIAPMYAF
ALSR
NGNLIAPMYAF
ALSR
SAKLRMVTGLR
NIPS
SAKLRMVTGLR
NIPS
NGITNKVNTVIE
KMN
NGITNKVNTVIE
KMN
FHDSNVKNLYE
KVKS
FHDSNVKNLYE
KVKS
DGVKLESMGIY
QILA

13
G
LVLLCALAAAD
ADTI
LVLLCALAAAD
ADTI
GKCNIAGWLLG
NPEC
GKCNIAGWLLG
NPEC
FPKESSWPNHN
TNGV
FPKESSWPNHN
TNGV
PSNSKEQQNLY
QNEN
PSNSKEQQNLY
QNEN
GNLIAPMYAFA
LSRG
GNLIAPMYAFA
LSRG
AKLRMVTGLR
NIPSI
AKLRMVTGLR
NIPSI
GITNKVNTVIEK
MNI
GITNKVNTVIEK
MNI
HDSNVKNLYEK
VKSQ
HDSNVKNLYEK
VKSQ
GVKLESMGIYQ
ILAI

14
EQKLISEEDL
VLLCALAAADA
DTIC
VLLCALAAADA
DTIC
KCNIAGWLLGN
PECD
KCNIAGWLLGN
PECD
PKESSWPNHNT
NGVT
PKESSWPNHNT
NGVT
SNSKEQQNLYQ
NENA
SNSKEQQNLYQ
NENA
NLIAPMYAFAL
SRGF
NLIAPMYAFAL
SRGF
KLRMVTGLRNI
PSIQ
KLRMVTGLRNI
PSIQ
ITNKVNTVIEK
MNIQ
ITNKVNTVIEK
MNIQ
DSNVKNLYEKV
KSQL
DSNVKNLYEKV
KSQL
VKLESMGIYQIL
AIY

15
G
LLCALAAADAD
TICI
LLCALAAADAD
TICI
CNIAGWLLGNP
ECDP
CNIAGWLLGNP
ECDP
KESSWPNHNTN
GVTA
KESSWPNHNTN
GVTA
NSKEQQNLYQN
ENAY
NSKEQQNLYQN
ENAY
LIAPMYAFALS
RGFG
LIAPMYAFALS
RGFG
LRMVTGLRNIP
SIQS
LRMVTGLRNIP
SIQS
TNKVNTVIEKM
NIQF
TNKVNTVIEKM
NIQF
SNVKNLYEKVK
SQLK
SNVKNLYEKVK
SQLK
KLESMGIYQILA
IYS
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18

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

1
2
3
4

DGVKLESMGIY
QILA
EQKLISEEDL

GVKLESMGIYQ
ILAI
G

VKLESMGIYQIL
AIY
EQKLISEEDL

KLESMGIYQILA
IYS
G

16
EQKLISEEDL
LCALAAADADT
ICIG
LCALAAADADT
ICIG
NIAGWLLGNPE
CDPL
NIAGWLLGNPE
CDPL
ESSWPNHNTNG
VTAA
ESSWPNHNTNG
VTAA
SKEQQNLYQNE
NAYV
SKEQQNLYQNE
NAYV
IAPMYAFALSR
GFGS
IAPMYAFALSR
GFGS
RMVTGLRNIPSI
QSR
RMVTGLRNIPSI
QSR
NKVNTVIEKMN
IQFT
NKVNTVIEKMN
IQFT
NVKNLYEKVKS
QLKN
NVKNLYEKVKS
QLKN
LESMGIYQILAI
YST
LESMGIYQILAI
YST
EQKLISEEDL

17
G
CALAAADADTI
CIGY
CALAAADADTI
CIGY
IAGWLLGNPEC
DPLL
IAGWLLGNPEC
DPLL
SSWPNHNTNGV
TAAC
SSWPNHNTNGV
TAAC
KEQQNLYQNE
NAYVS
KEQQNLYQNE
NAYVS
APMYAFALSRG
FGSG
APMYAFALSRG
FGSG
MVTGLRNIPSIQ
SRG
MVTGLRNIPSIQ
SRG
KVNTVIEKMNI
QFTA
KVNTVIEKMNI
QFTA
VKNLYEKVKSQ
LKNN
VKNLYEKVKSQ
LKNN
ESMGIYQILAIY
STV
ESMGIYQILAIY
STV
G

18
EQKLISEEDL
ALAAADADTIC
IGYH
ALAAADADTIC
IGYH
AGWLLGNPEC
DPLLP
AGWLLGNPEC
DPLLP
SWPNHNTNGV
TAACS
SWPNHNTNGV
TAACS
EQQNLYQNEN
AYVSV
EQQNLYQNEN
AYVSV
PMYAFALSRGF
GSGI
PMYAFALSRGF
GSGI
VTGLRNIPSIQS
RGL
VTGLRNIPSIQS
RGL
VNTVIEKMNIQ
FTAV
VNTVIEKMNIQ
FTAV
KNLYEKVKSQL
KNNA
KNLYEKVKSQL
KNNA
SMGIYQILAIYS
TVA
SMGIYQILAIYS
TVA
EQKLISEEDL

19
G
LAAADADTICI
GYHA
LAAADADTICI
GYHA
GWLLGNPECDP
LLPV
GWLLGNPECDP
LLPV
WPNHNTNGVT
AACSH
WPNHNTNGVT
AACSH
QQNLYQNENA
YVSVV
QQNLYQNENA
YVSVV
MYAFALSRGFG
SGII
MYAFALSRGFG
SGII
TGLRNIPSIQSR
GLF
TGLRNIPSIQSR
GLF
NTVIEKMNIQFT
AVG
NTVIEKMNIQFT
AVG
NLYEKVKSQLK
NNAK
NLYEKVKSQLK
NNAK
MGIYQILAIYST
VAS
MGIYQILAIYST
VAS
G

20
EQKLISEEDL
AAADADTICIG
YHAN
AAADADTICIG
YHAN
WLLGNPECDPL
LPVR
WLLGNPECDPL

21
G
AADADTICIGY
HANN
AADADTICIGY
HANN
LLGNPECDPLLP
VRS
LLGNPECDPLLP

22
EQKLISEEDL
ADADTICIGYH
ANNS
ADADTICIGYH
ANNS
LGNPECDPLLP
VRSW
LGNPECDPLLP

23
G
DADTICIGYHA
NNST
DADTICIGYHA
NNST
GNPECDPLLPV
RSWS
GNPECDPLLPV
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5
6
7
8
9
10
11
12
13
14
15
16
17
18

1
2
3
4
5
6
7
8
9
10

LPVR
PNHNTNGVTAA
CSHE
PNHNTNGVTAA
CSHE
QNLYQNENAY
VSVVT
QNLYQNENAY
VSVVT
YAFALSRGFGS
GIIT
YAFALSRGFGS
GIIT
GLRNIPSIQSRG
LFG
GLRNIPSIQSRG
LFG
TVIEKMNIQFTA
VGK
TVIEKMNIQFTA
VGK
LYEKVKSQLKN
NAKE
LYEKVKSQLKN
NAKE
GIYQILAIYSTV
ASS
GIYQILAIYSTV
ASS
EQKLISEEDL

VRS
NHNTNGVTAA
CSHEG
NHNTNGVTAA
CSHEG
NLYQNENAYVS
VVTS
NLYQNENAYVS
VVTS
AFALSRGFGSGI
ITS
AFALSRGFGSGI
ITS
LRNIPSIQSRGL
FGA
LRNIPSIQSRGL
FGA
VIEKMNIQFTA
VGKE
VIEKMNIQFTA
VGKE
YEKVKSQLKNN
AKEI
YEKVKSQLKNN
AKEI
IYQILAIYSTVA
SSL
IYQILAIYSTVA
SSL
G

VRSW
HNTNGVTAACS
HEGK
HNTNGVTAACS
HEGK
LYQNENAYVSV
VTSN
LYQNENAYVSV
VTSN
FALSRGFGSGII
TSN
FALSRGFGSGII
TSN
RNIPSIQSRGLF
GAI
RNIPSIQSRGLF
GAI
IEKMNIQFTAV
GKEF
IEKMNIQFTAV
GKEF
EKVKSQLKNNA
KEIG
EKVKSQLKNNA
KEIG
YQILAIYSTVAS
SLV
YQILAIYSTVAS
SLV
EQKLISEEDL

RSWS
NTNGVTAACSH
EGKS
NTNGVTAACSH
EGKS
YQNENAYVSV
VTSNY
YQNENAYVSV
VTSNY
ALSRGFGSGIIT
SNA
ALSRGFGSGIIT
SNA
NIPSIQSRGLFG
AIA
NIPSIQSRGLFG
AIA
EKMNIQFTAVG
KEFN
EKMNIQFTAVG
KEFN
KVKSQLKNNA
KEIGN
KVKSQLKNNA
KEIGN
QILAIYSTVASS
LVL
QILAIYSTVASS
LVL
G

24
EQKLISEEDL
ADTICIGYHAN
NSTD
ADTICIGYHAN
NSTD
NPECDPLLPVRS
WSY
NPECDPLLPVRS
WSY
TNGVTAACSHE
GKSS
TNGVTAACSHE
GKSS
QNENAYVSVVT
SNYN
QNENAYVSVVT
SNYN
LSRGFGSGIITS
NAS
LSRGFGSGIITS
NAS

25
G
DTICIGYHANNS
TDT
DTICIGYHANNS
TDT
PECDPLLPVRS
WSYI
PECDPLLPVRS
WSYI
NGVTAACSHEG
KSSF
NGVTAACSHEG
KSSF
NENAYVSVVTS
NYNR
NENAYVSVVTS
NYNR
SRGFGSGIITSN
ASM
SRGFGSGIITSN
ASM

26
EQKLISEEDL
TICIGYHANNST
DTV
TICIGYHANNST
DTV
ECDPLLPVRSW
SYIV
ECDPLLPVRSW
SYIV
GVTAACSHEGK
SSFY
GVTAACSHEGK
SSFY
ENAYVSVVTSN
YNRR
ENAYVSVVTSN
YNRR
RGFGSGIITSNA
SMH
RGFGSGIITSNA
SMH

27
G
ICIGYHANNSTD
TVD
ICIGYHANNSTD
TVD
CDPLLPVRSWS
YIVE
CDPLLPVRSWS
YIVE
VTAACSHEGKS
SFYR
VTAACSHEGKS
SFYR
NAYVSVVTSNY
NRRF
NAYVSVVTSNY
NRRF
GFGSGIITSNAS
MHE
GFGSGIITSNAS
MHE
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IPSIQSRGLFGAI
AG
IPSIQSRGLFGAI
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KMNIQFTAVGK
EFNK
KMNIQFTAVGK
EFNK
VKSQLKNNAKE
IGNG
VKSQLKNNAKE
IGNG
ILAIYSTVASSL
VLL
ILAIYSTVASSL
VLL
EQKLISEEDL

PSIQSRGLFGAI
AGF
PSIQSRGLFGAI
AGF
MNIQFTAVGKE
FNKL
MNIQFTAVGKE
FNKL
KSQLKNNAKEI
GNGC
KSQLKNNAKEI
GNGC
LAIYSTVASSLV
LLV
LAIYSTVASSLV
LLV
G

SIQSRGLFGAIA
GFI
SIQSRGLFGAIA
GFI
NIQFTAVGKEF
NKLE
NIQFTAVGKEF
NKLE
SQLKNNAKEIG
NGCF
SQLKNNAKEIG
NGCF
AIYSTVASSLVL
LVS
AIYSTVASSLVL
LVS
EQKLISEEDL

IQSRGLFGAIAG
FIE
IQSRGLFGAIAG
FIE
IQFTAVGKEFN
KLEK
IQFTAVGKEFN
KLEK
QLKNNAKEIGN
GCFE
QLKNNAKEIGN
GCFE
IYSTVASSLVLL
VSL
IYSTVASSLVLL
VSL
G

28
EQKLISEEDL
CIGYHANNSTD
TVDT
CIGYHANNSTD
TVDT
DPLLPVRSWSYI
VET
DPLLPVRSWSYI
VET
TAACSHEGKSS
FYRN
TAACSHEGKSS
FYRN
AYVSVVTSNYN
RRFT
AYVSVVTSNYN
RRFT
FGSGIITSNASM
HEC
FGSGIITSNASM
HEC
QSRGLFGAIAG
FIEG
QSRGLFGAIAG
FIEG
QFTAVGKEFNK
LEKR
QFTAVGKEFNK
LEKR
LKNNAKEIGNG
CFEF
LKNNAKEIGNG
CFEF
YSTVASSLVLL
VSLG

29
G
IGYHANNSTDT
VDTV
IGYHANNSTDT
VDTV
PLLPVRSWSYIV
ETP
PLLPVRSWSYIV
ETP
AACSHEGKSSF
YRNL
AACSHEGKSSF
YRNL
YVSVVTSNYNR
RFTP
YVSVVTSNYNR
RFTP
GSGIITSNASMH
ECN
GSGIITSNASMH
ECN
SRGLFGAIAGFI
EGG
SRGLFGAIAGFI
EGG
FTAVGKEFNKL
EKRM
FTAVGKEFNKL
EKRM
KNNAKEIGNGC
FEFY
KNNAKEIGNGC
FEFY
STVASSLVLLVS
LGA

30
EQKLISEEDL
GYHANNSTDTV
DTVL
GYHANNSTDTV
DTVL
LLPVRSWSYIV
ETPN
LLPVRSWSYIV
ETPN
ACSHEGKSSFY
RNLL
ACSHEGKSSFY
RNLL
VSVVTSNYNRR
FTPE
VSVVTSNYNRR
FTPE
SGIITSNASMHE
CNT
SGIITSNASMHE
CNT
RGLFGAIAGFIE
GGW
RGLFGAIAGFIE
GGW
TAVGKEFNKLE
KRME
TAVGKEFNKLE
KRME
NNAKEIGNGCF
EFYH
NNAKEIGNGCF
EFYH
TVASSLVLLVS
LGAI

31
G
YHANNSTDTVD
TVLE
YHANNSTDTVD
TVLE
LPVRSWSYIVE
TPNS
LPVRSWSYIVE
TPNS
CSHEGKSSFYR
NLLW
CSHEGKSSFYR
NLLW
SVVTSNYNRRF
TPEI
SVVTSNYNRRF
TPEI
GIITSNASMHEC
NTK
GIITSNASMHEC
NTK
GLFGAIAGFIEG
GWT
GLFGAIAGFIEG
GWT
AVGKEFNKLEK
RMEN
AVGKEFNKLEK
RMEN
NAKEIGNGCFE
FYHK
NAKEIGNGCFE
FYHK
VASSLVLLVSL
GAIS

133

18

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

1
2
3
4

YSTVASSLVLL
VSLG
EQKLISEEDL

STVASSLVLLVS
LGA
G

TVASSLVLLVS
LGAI
EQKLISEEDL

VASSLVLLVSL
GAIS
G

32
EQKLISEEDL
HANNSTDTVDT
VLEK
HANNSTDTVDT
VLEK
PVRSWSYIVETP
NSE
PVRSWSYIVETP
NSE
SHEGKSSFYRN
LLWL
SHEGKSSFYRN
LLWL
VVTSNYNRRFT
PEIA
VVTSNYNRRFT
PEIA
IITSNASMHECN
TKC
IITSNASMHECN
TKC
LFGAIAGFIEGG
WTG
LFGAIAGFIEGG
WTG
VGKEFNKLEKR
MENL
VGKEFNKLEKR
MENL
AKEIGNGCFEF
YHKC
AKEIGNGCFEF
YHKC
ASSLVLLVSLG
AISF
ASSLVLLVSLG
AISF
EQKLISEEDL

33
G
ANNSTDTVDTV
LEKN
ANNSTDTVDTV
LEKN
VRSWSYIVETP
NSEN
VRSWSYIVETP
NSEN
HEGKSSFYRNL
LWLT
HEGKSSFYRNL
LWLT
VTSNYNRRFTP
EIAE
VTSNYNRRFTP
EIAE
ITSNASMHECN
TKCQ
ITSNASMHECN
TKCQ
FGAIAGFIEGG
WTGM
FGAIAGFIEGG
WTGM
GKEFNKLEKRM
ENLN
GKEFNKLEKRM
ENLN
KEIGNGCFEFY
HKCD
KEIGNGCFEFY
HKCD
SSLVLLVSLGAI
SFW
SSLVLLVSLGAI
SFW
G

34
EQKLISEEDL
NNSTDTVDTVL
EKNV
NNSTDTVDTVL
EKNV
RSWSYIVETPNS
ENG
RSWSYIVETPNS
ENG
EGKSSFYRNLL
WLTE
EGKSSFYRNLL
WLTE
TSNYNRRFTPEI
AER
TSNYNRRFTPEI
AER
TSNASMHECNT
KCQT
TSNASMHECNT
KCQT
GAIAGFIEGGW
TGMI
GAIAGFIEGGW
TGMI
KEFNKLEKRME
NLNK
KEFNKLEKRME
NLNK
EIGNGCFEFYH
KCDN
EIGNGCFEFYH
KCDN
SLVLLVSLGAIS
FWM
SLVLLVSLGAIS
FWM
EQKLISEEDL

35
G
NSTDTVDTVLE
KNVT
NSTDTVDTVLE
KNVT
SWSYIVETPNSE
NGI
SWSYIVETPNSE
NGI
GKSSFYRNLLW
LTEK
GKSSFYRNLLW
LTEK
SNYNRRFTPEIA
ERP
SNYNRRFTPEIA
ERP
SNASMHECNTK
CQTP
SNASMHECNTK
CQTP
AIAGFIEGGWT
GMID
AIAGFIEGGWT
GMID
EFNKLEKRMEN
LNKK
EFNKLEKRMEN
LNKK
IGNGCFEFYHK
CDNE
IGNGCFEFYHK
CDNE
LVLLVSLGAISF
WMC
LVLLVSLGAISF
WMC
G

36
EQKLISEEDL
STDTVDTVLEK
NVTV
STDTVDTVLEK
NVTV
WSYIVETPNSE
NGIC
WSYIVETPNSE

37
G
TDTVDTVLEKN
VTVT
TDTVDTVLEKN
VTVT
SYIVETPNSENG
ICY
SYIVETPNSENG

38
EQKLISEEDL
DTVDTVLEKNV
TVTH
DTVDTVLEKNV
TVTH
YIVETPNSENGI
CYP
YIVETPNSENGI

39
G
TVDTVLEKNVT
VTHS
TVDTVLEKNVT
VTHS
IVETPNSENGIC
YPG
IVETPNSENGIC
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NGIC
KSSFYRNLLWL
TEKE
KSSFYRNLLWL
TEKE
NYNRRFTPEIAE
RPK
NYNRRFTPEIAE
RPK
NASMHECNTK
CQTPL
NASMHECNTK
CQTPL
IAGFIEGGWTG
MIDG
IAGFIEGGWTG
MIDG
FNKLEKRMENL
NKKV
FNKLEKRMENL
NKKV
GNGCFEFYHKC
DNEC
GNGCFEFYHKC
DNEC
VLLVSLGAISF
WMCS
VLLVSLGAISF
WMCS
EQKLISEEDL

ICY
SSFYRNLLWLT
EKEG
SSFYRNLLWLT
EKEG
YNRRFTPEIAER
PKV
YNRRFTPEIAER
PKV
ASMHECNTKC
QTPLG
ASMHECNTKC
QTPLG
AGFIEGGWTGM
IDGW
AGFIEGGWTGM
IDGW
NKLEKRMENL
NKKVD
NKLEKRMENL
NKKVD
NGCFEFYHKCD
NECM
NGCFEFYHKCD
NECM
LLVSLGAISFW
MCSN
LLVSLGAISFW
MCSN
G

CYP
SFYRNLLWLTE
KEGS
SFYRNLLWLTE
KEGS
NRRFTPEIAERP
KVR
NRRFTPEIAERP
KVR
SMHECNTKCQT
PLGA
SMHECNTKCQT
PLGA
GFIEGGWTGMI
DGWY
GFIEGGWTGMI
DGWY
KLEKRMENLN
KKVDD
KLEKRMENLN
KKVDD
GCFEFYHKCDN
ECME
GCFEFYHKCDN
ECME
LVSLGAISFWM
CSNG
LVSLGAISFWM
CSNG
EQKLISEEDL

YPG
FYRNLLWLTEK
EGSY
FYRNLLWLTEK
EGSY
RRFTPEIAERPK
VRD
RRFTPEIAERPK
VRD
MHECNTKCQTP
LGAI
MHECNTKCQTP
LGAI
FIEGGWTGMID
GWYG
FIEGGWTGMID
GWYG
LEKRMENLNK
KVDDG
LEKRMENLNK
KVDDG
CFEFYHKCDNE
CMES
CFEFYHKCDNE
CMES
VSLGAISFWMC
SNGS
VSLGAISFWMC
SNGS
G

40
EQKLISEEDL
VDTVLEKNVTV
THSV
VDTVLEKNVTV
THSV
VETPNSENGICY
PGD
VETPNSENGICY
PGD
YRNLLWLTEKE
GSYP
YRNLLWLTEKE
GSYP
RFTPEIAERPKV
RDQ
RFTPEIAERPKV
RDQ
HECNTKCQTPL
GAIN
HECNTKCQTPL
GAIN

41
G
DTVLEKNVTVT
HSVN
DTVLEKNVTVT
HSVN
ETPNSENGICYP
GDF
ETPNSENGICYP
GDF
RNLLWLTEKEG
SYPN
RNLLWLTEKEG
SYPN
FTPEIAERPKVR
DQA
FTPEIAERPKVR
DQA
ECNTKCQTPLG
AINS
ECNTKCQTPLG
AINS

42
EQKLISEEDL
TVLEKNVTVTH
SVNL
TVLEKNVTVTH
SVNL
TPNSENGICYPG
DFI
TPNSENGICYPG
DFI
NLLWLTEKEGS
YPNL
NLLWLTEKEGS
YPNL
TPEIAERPKVRD
QAG
TPEIAERPKVRD
QAG
CNTKCQTPLGA
INSS
CNTKCQTPLGA
INSS

43
G
VLEKNVTVTHS
VNLL
VLEKNVTVTHS
VNLL
PNSENGICYPG
DFID
PNSENGICYPG
DFID
LLWLTEKEGSY
PNLK
LLWLTEKEGSY
PNLK
PEIAERPKVRD
QAGR
PEIAERPKVRD
QAGR
NTKCQTPLGAI
NSSL
NTKCQTPLGAI
NSSL
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IEGGWTGMIDG
WYGY
IEGGWTGMIDG
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EKRMENLNKK
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FEFYHKCDNEC
MESV
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SLGAISFWMCS
NGSL
SLGAISFWMCS
NGSL
EQKLISEEDL

EGGWTGMIDG
WYGYH
EGGWTGMIDG
WYGYH
KRMENLNKKV
DDGFL
KRMENLNKKV
DDGFL
EFYHKCDNEC
MESVR
EFYHKCDNEC
MESVR
LGAISFWMCSN
GSLQ
LGAISFWMCSN
GSLQ
G

GGWTGMIDGW
YGYHH
GGWTGMIDGW
YGYHH
RMENLNKKVD
DGFLD
RMENLNKKVD
DGFLD
FYHKCDNECM
ESVRN
FYHKCDNECM
ESVRN
GAISFWMCSNG
SLQC
GAISFWMCSNG
SLQC
EQKLISEEDL

GWTGMIDGWY
GYHHQ
GWTGMIDGWY
GYHHQ
MENLNKKVDD
GFLDI
MENLNKKVDD
GFLDI
YHKCDNECME
SVRNG
YHKCDNECME
SVRNG
AISFWMCSNGS
LQCR
AISFWMCSNGS
LQCR
G

44
EQKLISEEDL
LEKNVTVTHSV
NLLE
LEKNVTVTHSV
NLLE
NSENGICYPGD
FIDY
NSENGICYPGD
FIDY
LWLTEKEGSYP
NLKN
LWLTEKEGSYP
NLKN
EIAERPKVRDQ
AGRM
EIAERPKVRDQ
AGRM
TKCQTPLGAINS
SLP
TKCQTPLGAINS
SLP
WTGMIDGWYG
YHHQN
WTGMIDGWYG
YHHQN
ENLNKKVDDGF
LDIW
ENLNKKVDDGF
LDIW
HKCDNECMES
VRNGT
HKCDNECMES
VRNGT
ISFWMCSNGSL
QCRI

45
G
EKNVTVTHSVN
LLED
EKNVTVTHSVN
LLED
SENGICYPGDFI
DYE
SENGICYPGDFI
DYE
WLTEKEGSYPN
LKNS
WLTEKEGSYPN
LKNS
IAERPKVRDQA
GRMN
IAERPKVRDQA
GRMN
KCQTPLGAINSS
LPY
KCQTPLGAINSS
LPY
TGMIDGWYGY
HHQNE
TGMIDGWYGY
HHQNE
NLNKKVDDGFL
DIWT
NLNKKVDDGFL
DIWT
KCDNECMESVR
NGTY
KCDNECMESVR
NGTY
SFWMCSNGSLQ
CRIC

46
EQKLISEEDL
KNVTVTHSVNL
LEDS
KNVTVTHSVNL
LEDS
ENGICYPGDFID
YEE
ENGICYPGDFID
YEE
LTEKEGSYPNL
KNSY
LTEKEGSYPNL
KNSY
AERPKVRDQAG
RMNY
AERPKVRDQAG
RMNY
CQTPLGAINSSL
PYQ
CQTPLGAINSSL
PYQ
GMIDGWYGYH
HQNEQ
GMIDGWYGYH
HQNEQ
LNKKVDDGFLD
IWTY
LNKKVDDGFLD
IWTY
CDNECMESVRN
GTYD
CDNECMESVRN
GTYD
FWMCSNGSLQ
CRICI

47
G
NVTVTHSVNLL
EDSH
NVTVTHSVNLL
EDSH
NGICYPGDFIDY
EEL
NGICYPGDFIDY
EEL
TEKEGSYPNLK
NSYV
TEKEGSYPNLK
NSYV
ERPKVRDQAGR
MNYY
ERPKVRDQAGR
MNYY
QTPLGAINSSLP
YQN
QTPLGAINSSLP
YQN
MIDGWYGYHH
QNEQG
MIDGWYGYHH
QNEQG
NKKVDDGFLDI
WTYN
NKKVDDGFLDI
WTYN
DNECMESVRN
GTYDY
DNECMESVRN
GTYDY
WMCSNGSLQC
RICIG
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ISFWMCSNGSL
QCRI
EQKLISEEDL

SFWMCSNGSLQ
CRIC
G

FWMCSNGSLQ
CRICI
EQKLISEEDL

WMCSNGSLQC
RICIG
G

48
EQKLISEEDL
VTVTHSVNLLE
DSHN
VTVTHSVNLLE
DSHN
GICYPGDFIDYE
ELR
GICYPGDFIDYE
ELR
EKEGSYPNLKN
SYVN
EKEGSYPNLKN
SYVN
RPKVRDQAGR
MNYYW
RPKVRDQAGR
MNYYW
TPLGAINSSLPY
QNI
TPLGAINSSLPY
QNI
IDGWYGYHHQ
NEQGS
IDGWYGYHHQ
NEQGS
KKVDDGFLDIW
TYNA
KKVDDGFLDIW
TYNA
NECMESVRNGT
YDYP
NECMESVRNGT
YDYP
MCSNGSLQCRI
CIGS
MCSNGSLQCRI
CIGS
EQKLISEEDL

49
G
TVTHSVNLLED
SHNG
TVTHSVNLLED
SHNG
ICYPGDFIDYEE
LRE
ICYPGDFIDYEE
LRE
KEGSYPNLKNS
YVNK
KEGSYPNLKNS
YVNK
PKVRDQAGRM
NYYWT
PKVRDQAGRM
NYYWT
PLGAINSSLPYQ
NIH
PLGAINSSLPYQ
NIH
DGWYGYHHQN
EQGSG
DGWYGYHHQN
EQGSG
KVDDGFLDIWT
YNAE
KVDDGFLDIWT
YNAE
ECMESVRNGTY
DYPK
ECMESVRNGTY
DYPK
CSNGSLQCRICI
GSG
CSNGSLQCRICI
GSG
G

50
EQKLISEEDL
VTHSVNLLEDS
HNGK
VTHSVNLLEDS
HNGK
CYPGDFIDYEEL
REQ
CYPGDFIDYEEL
REQ
EGSYPNLKNSY
VNKK
EGSYPNLKNSY
VNKK
KVRDQAGRMN
YYWTL
KVRDQAGRMN
YYWTL
LGAINSSLPYQN
IHP
LGAINSSLPYQN
IHP
GWYGYHHQNE
QGSGY
GWYGYHHQNE
QGSGY
VDDGFLDIWTY
NAEL
VDDGFLDIWTY
NAEL
CMESVRNGTY
DYPKY
CMESVRNGTY
DYPKY
SNGSLQCRICIG
SGS
SNGSLQCRICIG
SGS
EQKLISEEDL

51
G
THSVNLLEDSH
NGKL
THSVNLLEDSH
NGKL
YPGDFIDYEELR
EQL
YPGDFIDYEELR
EQL
GSYPNLKNSYV
NKKG
GSYPNLKNSYV
NKKG
VRDQAGRMNY
YWTLL
VRDQAGRMNY
YWTLL
GAINSSLPYQNI
HPV
GAINSSLPYQNI
HPV
WYGYHHQNEQ
GSGYA
WYGYHHQNEQ
GSGYA
DDGFLDIWTYN
AELL
DDGFLDIWTYN
AELL
MESVRNGTYD
YPKYS
MESVRNGTYD
YPKYS
NGSLQCRICIGS
GSG
NGSLQCRICIGS
GSG
G

52
EQKLISEEDL
HSVNLLEDSHN
GKLC
HSVNLLEDSHN
GKLC
PGDFIDYEELRE
QLS
PGDFIDYEELRE

53
G
SVNLLEDSHNG
KLCR
SVNLLEDSHNG
KLCR
GDFIDYEELRE
QLSS
GDFIDYEELRE

54
EQKLISEEDL
VNLLEDSHNGK
LCRL
VNLLEDSHNGK
LCRL
DFIDYEELREQL
SSV
DFIDYEELREQL

55
G
NLLEDSHNGKL
CRLK
NLLEDSHNGKL
CRLK
FIDYEELREQLS
SVS
FIDYEELREQLS
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QLS
SYPNLKNSYVN
KKGK
SYPNLKNSYVN
KKGK
RDQAGRMNYY
WTLLK
RDQAGRMNYY
WTLLK
AINSSLPYQNIH
PVT
AINSSLPYQNIH
PVT
YGYHHQNEQG
SGYAA
YGYHHQNEQG
SGYAA
DGFLDIWTYNA
ELLV
DGFLDIWTYNA
ELLV
ESVRNGTYDYP
KYSE
ESVRNGTYDYP
KYSE
GSLQCRICIGSG
SGS
GSLQCRICIGSG
SGS
EQKLISEEDL

QLSS
YPNLKNSYVNK
KGKE
YPNLKNSYVNK
KGKE
DQAGRMNYYW
TLLKP
DQAGRMNYYW
TLLKP
INSSLPYQNIHP
VTI
INSSLPYQNIHP
VTI
GYHHQNEQGS
GYAAD
GYHHQNEQGS
GYAAD
GFLDIWTYNAE
LLVL
GFLDIWTYNAE
LLVL
SVRNGTYDYPK
YSEE
SVRNGTYDYPK
YSEE
SLQCRICIGSGS
GSG
SLQCRICIGSGS
GSG
G

SSV
PNLKNSYVNKK
GKEV
PNLKNSYVNKK
GKEV
QAGRMNYYWT
LLKPG
QAGRMNYYWT
LLKPG
NSSLPYQNIHPV
TIG
NSSLPYQNIHPV
TIG
YHHQNEQGSG
YAADQ
YHHQNEQGSG
YAADQ
FLDIWTYNAEL
LVLL
FLDIWTYNAEL
LVLL
VRNGTYDYPK
YSEES
VRNGTYDYPK
YSEES

SVS
NLKNSYVNKK
GKEVL
NLKNSYVNKK
GKEVL
AGRMNYYWTL
LKPGD
AGRMNYYWTL
LKPGD
SSLPYQNIHPVT
IGE
SSLPYQNIHPVT
IGE
HHQNEQGSGY
AADQK
HHQNEQGSGY
AADQK
LDIWTYNAELL
VLLE
LDIWTYNAELL
VLLE
RNGTYDYPKYS
EESK
RNGTYDYPKYS
EESK

EQKLISEEDL

G
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EQKLISEEDL
LLEDSHNGKLC
RLKG
LLEDSHNGKLC
RLKG
IDYEELREQLSS
VSS
IDYEELREQLSS
VSS
LKNSYVNKKG
KEVLV
LKNSYVNKKG
KEVLV
GRMNYYWTLL
KPGDT
GRMNYYWTLL
KPGDT
SLPYQNIHPVTI
GEC
SLPYQNIHPVTI
GEC

57
G
LEDSHNGKLCR
LKGI
LEDSHNGKLCR
LKGI
DYEELREQLSS
VSSF
DYEELREQLSS
VSSF
KNSYVNKKGK
EVLVL
KNSYVNKKGK
EVLVL
RMNYYWTLLK
PGDTI
RMNYYWTLLK
PGDTI
LPYQNIHPVTIG
ECP
LPYQNIHPVTIG
ECP

58
EQKLISEEDL
EDSHNGKLCRL
KGIA
EDSHNGKLCRL
KGIA
YEELREQLSSVS
SFE
YEELREQLSSVS
SFE
NSYVNKKGKE
VLVLW
NSYVNKKGKE
VLVLW
MNYYWTLLKP
GDTII
MNYYWTLLKP
GDTII
PYQNIHPVTIGE
CPK
PYQNIHPVTIGE
CPK

59
G
DSHNGKLCRLK
GIAP
DSHNGKLCRLK
GIAP
EELREQLSSVSS
FER
EELREQLSSVSS
FER
SYVNKKGKEVL
VLWG
SYVNKKGKEVL
VLWG
NYYWTLLKPG
DTIIF
NYYWTLLKPG
DTIIF
YQNIHPVTIGEC
PKY
YQNIHPVTIGEC
PKY
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EQKLISEEDL
SHNGKLCRLKG
IAPL
SHNGKLCRLKG
IAPL
ELREQLSSVSSF
ERF
ELREQLSSVSSF
ERF
YVNKKGKEVL
VLWGI
YVNKKGKEVL
VLWGI
YYWTLLKPGDT
IIFE
YYWTLLKPGDT
IIFE
QNIHPVTIGECP
KYV
QNIHPVTIGECP
KYV
QGSGYAADQK
STQNA
QGSGYAADQK
STQNA
YNAELLVLLEN
ERTL
YNAELLVLLEN
ERTL
DYPKYSEESKL
NREK
DYPKYSEESKL
NREK

61
G
HNGKLCRLKGI
APLQ
HNGKLCRLKGI
APLQ
LREQLSSVSSFE
RFE
LREQLSSVSSFE
RFE
VNKKGKEVLV
LWGIH
VNKKGKEVLV
LWGIH
YWTLLKPGDTII
FEA
YWTLLKPGDTII
FEA
NIHPVTIGECPK
YVR
NIHPVTIGECPK
YVR
GSGYAADQKST
QNAI
GSGYAADQKST
QNAI
NAELLVLLENE
RTLD
NAELLVLLENE
RTLD
YPKYSEESKLN
REKV
YPKYSEESKLN
REKV

62
EQKLISEEDL
NGKLCRLKGIA
PLQL
NGKLCRLKGIA
PLQL
REQLSSVSSFER
FEI
REQLSSVSSFER
FEI
NKKGKEVLVL
WGIHH
NKKGKEVLVL
WGIHH
WTLLKPGDTIIF
EAN
WTLLKPGDTIIF
EAN
IHPVTIGECPKY
VRS
IHPVTIGECPKY
VRS
SGYAADQKSTQ
NAIN
SGYAADQKSTQ
NAIN
AELLVLLENER
TLDF
AELLVLLENER
TLDF
PKYSEESKLNR
EKVD
PKYSEESKLNR
EKVD

63
G
GKLCRLKGIAP
LQLG
GKLCRLKGIAP
LQLG
EQLSSVSSFERF
EIF
EQLSSVSSFERF
EIF
KKGKEVLVLW
GIHHP
KKGKEVLVLW
GIHHP
TLLKPGDTIIFE
ANG
TLLKPGDTIIFE
ANG
HPVTIGECPKY
VRSA
HPVTIGECPKY
VRSA
GYAADQKSTQ
NAING
GYAADQKSTQ
NAING
ELLVLLENERT
LDFH
ELLVLLENERT
LDFH
KYSEESKLNRE
KVDG
KYSEESKLNRE
KVDG

EQKLISEEDL

G

EQKLISEEDL

G

18

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
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1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

64
EQKLISEEDL
KLCRLKGIAPL
QLGK
KLCRLKGIAPL
QLGK
QLSSVSSFERFE
IFP
QLSSVSSFERFE
IFP
KGKEVLVLWGI
HHPS
KGKEVLVLWGI
HHPS
LLKPGDTIIFEA
NGN
LLKPGDTIIFEA
NGN
PVTIGECPKYV
RSAK
PVTIGECPKYV
RSAK
YAADQKSTQN
AINGI
YAADQKSTQN
AINGI
LLVLLENERTL
DFHD
LLVLLENERTL
DFHD
YSEESKLNREK
VDGV
YSEESKLNREK
VDGV

17
18
EQKLISEEDL

G
EQKLISEEDL
G
EQKLISEEDL
G
EQKLISEEDL
G
EQKLISEEDL
G
EQKLISEEDL
G
EQKLISEEDL
G
EQKLISEEDL
G
EQKLISEEDL
G
EQKLISEEDL
G
G
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